Topical compositions comprising a corticosteroid

ABSTRACT

Topical compositions comprising a corticosteroid, at least one alcohol, and a penetration enhancing agent.

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.15/068,428 filed Mar. 11, 2016, which is a continuation-in-part of U.S.patent application Ser. No. 14/645,297 filed Mar. 11, 2015, which claimspriority from U.S. Provisional Application Ser. No. 61/951,188 filedMar. 11, 2014, the entire disclosures of which are incorporated hereinby this reference.

TECHNICAL FIELD

The present invention relates to a topical composition comprising acorticosteroid and at least one penetration enhancing agent, wherein thecomposition is substantially free of propylene glycol.

BACKGROUND

Topical corticosteroids are the most frequently prescribed drugs bydermatologists for treating psoriasis, relief of the inflammatory andpruritic manifestations of steroid responsive dermatoses, and associateddiseases or disorders. The corticosteroids are a class of compoundscomprising steroids (lipids that contain a hydrogenatedcyclopentoperhydrophenanthrene ring system) elaborated by the adrenalcortex (except sex hormones of adrenal origin) in response to therelease of adrenocorticotrophin or adrenocorticotropic hormone by thepituitary gland, or to any synthetic equivalent, or to angiotensin II.In pharmacologic doses, corticosteroids are used primarily for theiranti-inflammatory and/or immunosuppressive effects.

Topical corticosteroids, such as clobetasol propionate, are effective intreatment of corticosteroid-responsive dermatoses primarily because oftheir anti-inflammatory, antipruritic and vasoconstrictive actions.Clobetasol propionate is used to treat various other skin disordersincluding eczema and psoriasis. It is also highly effective for contactdermatitis caused by exposure to poison ivy/oak.

Clobetasol propionate is chemically known as[17-(2′-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate and is represented by structural FormulaI:

Clobetasol propionate is commercially available in compositions fortopical application in the form of aerosol foam, cream, ointment, gel,solution, lotion, spray or shampoo, in a weight concentration of 0.05%.TEMOVATE® cream is a commercially available product of clobetasolapproved by U.S. Food and Drug Administration (FDA) on Dec. 27, 1985 andis currently being marketed by Fougera Pharms. TEMOVATE® cream containsClobetasol propionate 0.5 mg/g in a cream base of propylene glycol,glyceryl monostearate, cetostearyl alcohol, glyceryl stearate, PEG 100stearate, white wax, chlorocresol, sodium citrate, citric acidmonohydrate and purified water. TEMOVATE® E is another approved productby U.S. Food and Drug Administration (FDA) containing Clobetasolpropionate (0.05% (w/w)) in a cream base of cetostearyl alcohol,isopropyl myristate, propylene glycol, ceteth-20, dimethicone 350,citric acid monohydrate, sodium citrate, imidurea, and purified water.

U.S. Pat. No. 5,972,920 is related to a formulation characterized by acarrier compound formed of a combination of two components in a volumeratio of about 50/50, wherein a first carrier component is selected fromthe group consisting essentially of ethyl alcohol and isopropyl alcoholand a second carrier component is selected from the group consistingessentially of isopropyl myristate, isopropyl palmitate, octylpalmitate, octyl isononanoate, and isocetyl stearate. The formulationalso comprises an anionic surfactant.

PCT Application WO 2006/115987 is related to a method for treatingpsoriasis by spraying a pharmaceutical composition containing aneffective amount of clobetasol propionate onto the skin with psoriasis,using a daily treatment for at least 4 weeks. The preferred compositionis a spray formulation of clobetasol propionate 0.05%, containingalcohol, isopropyl myristate, an anionic surfactant such as sodiumlauryl sulfate, and optionally, an antimicrobial compound such as anantifungal compound, e.g., undecylenic acid.

U.S. Pat. Nos. 6,419,913 and 6,284,234 are related to topical deliverysystems for active agents comprising micellar compositions.

U.S. Publication No. 2006/0099173 is related to a process of making apharmaceutical composition for topical application, the compositionbeing an emulsion comprising water and at least one active ingredient.

U.S. Publication No. 2007/0142343 is related to a composition comprisingcorticosteroids, penetration enhancers, solvents and emulsifiers. Thevehicle of this composition utilizes at least two penetration enhancers,including diisopropyl adipate, dimethyl isosorbide, propylene glycol,1,2,6-hexanetriol, and benzyl alcohol.

US publication No. 2009/0104131 is related to a topically applicablecompositions in the form of oil-in-water (O/W) emulsions contain apro-penetrating system including at least one glycol and at least oneadditional pro-penetrating agent, a suitable emulsifying system and atleast one active agent of the family of steroidal anti-inflammatoryagents. Propylene glycol is disclosed as pro-penetrating agent.

U.S. Pat. No. 6,579,512 is related to topical spray compositioncomprising clobetasol propionate, ethanol, propellant and isopropylmyristate.

U.S. Pat. Nos. 7,700,081 and 7,316,810 are related to clobetasolpropionate (0.05 wt %) shampoo compositions used for washing andtreating the ailments of scalp.

Dermatological corticosteroids, in particular clobetasol propionatetopical preparations face multiple problems, such as deliveryefficiency, stability, and tolerability, in particular with respect toexcipients that would not cause irritation. In addition, corticosteroidscan be absorbed through the skin and can cause systemic side effects,for example hypothalamic pituitary adrenal (HPA) axis suppression.Therefore, to avoid unwanted side effects, the corticosteroid is used ata concentration as low as possible. However, topical preparationscontaining low concentrations corticosteroids cannot ensure a sufficienttherapeutic effect.

U.S. Publication No. 2010/0249060 is related to a low dose clobetasolpropionate composition in aqueous vehicle based on propylene glycol andmacrogol-glycerol hydroxysterate.

Although several of the above noted references disclose clobetasolpropionate containing compositions, most of them are greasy, and henceare unpleasant to apply on large areas of the skin. In addition, someconventional cream and ointment bases containing propylene glycol areirritating to the skin, particularly over the long exposure that isfrequently required for efficacy. The fluidity of lotions often makestheir physical application difficult to control over a desired area.Further, formulations containing ethanol or propylene glycol may beassociated with an elevated risk of sensitization and have a tendency toinduce irritation, and thus, such formulations do not promote patientcompliance. The currently available topical compositions comprisingclobetasol appears to show adverse effect on endocrine system asdescribed in TEMOVATE® cream and TEMOVATE® E cream labels(Hypothalamic-pituitary-adrenal axis suppression).

Accordingly, there is a long felt need to develop effective topicalclobetasol composition with reduced concentration of active, but havingan effect comparable to that obtainable with conventional topicalclobetasol propionate compositions. Further it is desirable to have aclobetasol propionate composition with improved absorption withoutcausing any skin irritation.

SUMMARY OF THE INVENTION

Accordingly, provided herein, in some embodiments, is a topicalpharmaceutical composition including at least one corticosteroid and atleast one penetration enhancing agent.

In some embodiments, a topical pharmaceutical composition includesbetween 0.015% and 0.035% (w/w) clobetasol; at least one alcoholselected from the group-consisting of fatty alcohols, PEGylated fattyalcohols, long chain alcohols, isopropyl alcohol, benzyl alcohol,branched aliphatic alcohols, lanolin alcohol, polyvinyl alcohols, andcombinations thereof; a penetration enhancing agent; an emulsifyingagent; an aqueous phase; and an oil phase. In one embodiment, theclobetasol is clobetasol propionate. In one embodiment, the penetrationenhancing agent is selected from group consisting of polyols, glycols(except propylene glycol), ethers, glycol ethers, esters, sulfoxides,fatty acids, fatty acid esters, essential oils, terpenes, terpenoids,PEGylated fatty acids, PEGylated fatty acid esters and mixtures thereofnitrogenous compounds, alkanones, organic acids, and combinationsthereof. In another embodiment, the penetration enhancing agent isdiethylene glycol monoethyl ether.

In some embodiments, the composition is an oil-in-water emulsion. Insome embodiments, the composition has a viscosity of from about 0.1 cPto about 500 cP when measured by Brookfield viscometer Cap 2000+ withspindle no. 1 at 530 rpm at 25° C. In some embodiments, the compositionis substantially free of propylene glycol. In some embodiments, thecomposition further includes at least one non-polymeric thickeningagent. In one embodiment, the non-polymeric thickening agent is selectedfrom the group consisting of cetyl alcohol, paraffin, stearyl alcohol,white wax, wax cetyl esters, microcrystalline wax, anionic emulsifyingwax, non-ionic emulsifying wax, yellow wax, castor oil, ceresin,cetostearyl alcohol, cyclomethicone, glyceryl behenate, hectorite,myristyl alcohol, cetylstearyl alcohol, triolein, lanolin, andcombinations thereof. In some embodiments, the aqueous phase includeswater. In some embodiments, the oil phase includes the penetrationenhancing agent.

Also provided herein, in some embodiments, is a method of treating askin disease or disorder, the method including topically administering atopical composition comprising between 0.015% and 0.035% (w/w)clobetasol; at least one alcohol selected from the group-consisting offatty alcohols, PEGylated fatty alcohols, long chain alcohols, isopropylalcohol, benzyl alcohol, branched aliphatic alcohols, lanolin alcohol,polyvinyl alcohols, and combinations thereof; a penetration enhancingagent; an emulsifying agent; an aqueous phase; and an oil phase to anindividual in need of treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows drug release for a composition of the invention and acommercially available product.

FIG. 2 shows drug release for a composition of the invention and acommercially available product.

FIG. 3 shows percent of inhibition of redness for an untreated control,compositions of the invention, and a commercially available product.

FIG. 4 shows and AUC of skin redness for an untreated control,compositions of the invention, and a commercially available product.

FIG. 5 shows efficacy analysis: Investigator's Global Assessment(IGA)—Example 5 Vs TEMOVATE® Cream.

FIG. 6 shows ACTH Stimulation Test Result (Serum Cortisol levels inug/dL).

FIG. 7 shows results of HPA axis suppression (ACTH stimulation test).

FIG. 8 shows mean plasma concentration of clobetasol propionate: Example5 Vs TEMOVATE® Cream.

DETAILED DESCRIPTION OF THE INVENTION

The details of one or more embodiments of the present invention are setforth in this document. Modifications to embodiments described in thisdocument, and other embodiments, will be evident to those of ordinaryskill in the art after a study of the information provided in thisdocument. The information provided in this document, and particularlythe specific details of the described exemplary embodiments, is providedprimarily for clearness of understanding and no unnecessary limitationsare to be understood therefrom. In case of conflict, the specificationof this document, including definitions, will control.

Definitions: The terms as used herein have the following meanings:

Clobetasol, as used herein, encompasses pharmaceutically acceptable,pharmacologically active derivatives of clobetasol, including clobetasolpropionate, clobetasol base form, its ester form, its isomer form, bothindividual enantiomers of clobetasol (dextrogyral and levogyralenantiomers) in their substantially pure form and their pharmaceuticallyacceptable salts, mixtures (in any ratio) of clobetasol enantiomers andtheir pharmaceutically acceptable salts, and active metabolites ofclobetasol and their pharmaceutically acceptable salts, unless otherwisenoted. The solid state form of clobetasol used in the composition of thepresent invention is not critical. For example, clobetasol propionatecan be amorphous or crystalline. As will be recognized by one ofordinary skill in the art upon study of this application, clobetasol(s)are corticosteroids. In some embodiment, the terms “active”, “activeagent”, or “compound” herein refers to corticosteroids, includingclobetasol, or to pharmaceutically acceptable forms thereof.

The term “low-dose clobetasol” means clobetasol is present in an amountfrom about 0.005% to about 0.045% (w/w). In some embodiments, low-doseclobetasol is provided from about 0.005% to about 0.045% (w/w). In someembodiments, low-dose clobetasol is provided at a dose of about 0.005%,0.01%, 0.015%, 0.02%, or 0.025% to about 0.03%, 0.035%, or 0.04% (w/w).In some embodiments, low-dose clobetasol is provided at a dose of about0.005%, 0.01%, 0.015%, 0.02%, or 0.025% to about 0.03%, 0.035%, or 0.04%(w/w) 0.045% (w/w).

The term “substantially free” as used herein indicates that thespecified substance referred to is present in amounts not more than 10%by weight of the total composition or in amounts not more than about 9%by weight of the total composition, or in amounts not more than about 8%by weight of the total composition, or in amounts not more than about 7%by weight of the total composition, or in amounts not more than about 6%by weight of the total composition, or in amounts not more than about 5%by weight of the total composition, or in amounts not more than about 4%by weight of the total composition, or in amounts not more than about 3%by weight of the total composition, or in amounts not more than about 2%by weight of the total composition or in amounts not more than about 1%by weight of the total composition or in an amount about 0% by weight ofthe total composition or completely free of specified substance i.e. 0%.

The term “pharmaceutically-acceptable” as used herein, means that inertexcipients are suitable for use in contact with the tissues of humansand lower animals without undue toxicity, incompatibility, instability,irritation, allergic response, and the like, commensurate with areasonable benefit/risk ratio.

The term “substantially free of adverse effects” as used herein means atleast about 90% of total patient population does not have adverseeffects resultant from clobetasol based compositions or about 80% oftotal patient population does not adverse effects or at least about 70%⁰of total patient population does not have adverse effects or at leastabout 60% of total patient population does not have adverse effects. Forexample, about 90% of total patient population does not have HPA axissuppression or about 80/o of total patient population does not have HPAaxis suppression or at least about 70% of total patient population doesnot have HPA axis suppression or at least about 60% of total patientpopulation does not have HPA axis suppression. In some embodiments,“substantially free of HPA axis suppression” as used herein means atleast about 90% of total patient population does not have HPA axissuppression or about 80% of total patient population does not HPA axissuppression or at least about 70% of total patient population does nothave HPA axis suppression or at least about 60% of total patientpopulation does not have HPA axis suppression. Another adverse effect isreduction in the serum concentration of DHEAS and the percentagereduction of serum concentration of DHEAS is less than about 18% or thepercentage reduction of serum concentration of DHEAS is less than about15%, the percentage reduction of serum concentration of DHEAS is lessthan about 12%.

The term “adverse effect” as used herein means adverse effects of thehigh-mid potent topical steroids such as clobetasol, and the adverseeffects are significant effect on endocrine system. Adverse effects asdefined in this application encompasses reversible suppression of thehypothalamic-pituitary-adrenal (HPA) axis and/or the reduction in theserum levels of dehydroepiandrosterone (DHEA) and/ordehydroepiandrosterone sulfate (DHEAS).

“Clinically significant” means a change that will produce an adversephysiological effect.

The term “highest approved topical dose of clobetasol” as used hereinrefers to a highest approved topical dose of clobetasol propionate by USFood and drug administration (US FDA) for the treatment of one or moreof skin disorders and the highest approved topical dose of clobetasolpropionate by US FDA is 0.05% (w/w), i.e. TEMOVATE® or TEMOVATE® E. Theterm “TEMOVATE®” is used interchangeably for indicating “highestapproved topical dose of clobetasol propionate’ i.e. 0.05% (w/w) incream or gel or ointment or solution form; or its pharmaceuticalequivalents or its therapeutic equivalents or later approved drugs whichare designated as AB rated by US FDA as per Approved Drug Products withTherapeutic Equivalence Evaluations (34^(th) edition) or drugs obtainedmarketing approval by US FDA through Abbreviated New Drug Application(ANDA) filing by establishing bioequivalence to such Product”. Forexample, TEMOVATE® Cream comprises clobetasol propionate 0.5 mg/g in acream base of propylene glycol, glyceryl monostearate, cetostearylalcohol, glyceryl stearate, PEG 100 stearate, white wax, chlorocresol,sodium citrate, citric acid monohydrate, and purified water. TEMOVATE®Ointment comprises clobetasol propionate 0.5 mg/g in a base of propyleneglycol, sorbitan sesquioleate, and white petrolatum. Excipient detailsof other compositions such Therapeutic equivalents/Pharmaceuticalequivalents of TEMOVATE® gel or TEMOVATE® gel or TEMOVATE® solution canbe found from US FDA or any other public literature. In some embodimentsTEMOVATE® includes its US FDA therapeutic or pharmaceutical equivalents.In some embodiments TEMOVATE® cream includes its US FDA therapeutic orpharmaceutical equivalents. TEMOVATE® is a Trademark originallyregistered by Glaxo Group Limited Corporation Great Britain Clargeshouse, 6-12 Clarges Street London England W1Y8DH. Last listed owner ofthis Trademark is Fougera Pharmaceuticals, inc. Corporation New York 60Baylis Road Melville N.Y. 11747.

The term “plasma concentrations of clobetasol” as used herein indicatesthat plasma concentrations of clobetasol base or its pharmaceuticallyacceptable salts or degradants, unless until specific salt form isdenoted; or in some embodiments “plasma concentrations of clobetasol”indicates plasma concentrations of clobetasol propionate or clobetasolbase.

The term “post treatment” as used herein to refer to the time periodpost to the topical treatment course of about 2 weeks or 15 days.

The term “clobetasol plasma levels insufficient to reduce serum levelscortisol less than or equal to 18 ug/dL” is used herein to indicate anyplasma concentration of clobetasol which does not provide HPA axissuppression to the subject treated with topical composition of thepresent invention, and such plasma concentrations may be selected fromabout 1000 pg/ml to about 10 pg/ml or below quantifiable limit (<=10pg/ml).

Terms such as “about,” “up to”, “generally”, “substantially” and thelike are to be construed as modifying a term or value such that it isnot an absolute. Such terms will be defined by the circumstances and theterms that they modify as those terms are understood by those of skillin the art. This includes, at very least, the degree of expectedexperimental error, technical error and instrumental error for a givenexperiment, technique or an instrument used to measure a value.

Unless otherwise indicated, all numbers expressing quantities ofingredients, properties such as reaction conditions, and so forth usedin the specification and claims are to be understood as being modifiedin all instances by the term “about”. Accordingly, unless indicated tothe contrary, the numerical parameters set forth in this specificationand claims are approximations that can vary depending upon the desiredproperties sought to be obtained by the present invention.

As used herein, ranges can be expressed as from “about” one particularvalue, and/or to “about” another particular value. It is also understoodthat there are a number of values disclosed herein, and that each valueis also herein disclosed as “about” that particular value in addition tothe value itself. For example, if the value “10” is disclosed, then“about 10” is also disclosed. It is also understood that each unitbetween two particular units are also disclosed. For example, if 10 and15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

The present invention can comprise or consist essentially of thecomponents of the present invention as well as other ingredients orelements described herein. As used herein, “comprising” means theelements recited, or their equivalent in structure or function, plus anyother element or elements which are not recited. The terms “having.”“including,” and “comprised of” are also to be construed as open endedunless the context suggests otherwise. As used herein, “consistingessentially of” means that the invention may include ingredients inaddition to those recited in the claim, but only if the additionalingredients do not materially alter the basic and novel characteristicsof the claimed invention.

As used herein, “optional” or “optionally” means that the subsequentlydescribed event or circumstance does or does not occur or exist and thatthe description includes instances where said event or circumstanceoccurs or exists, and instances where it does not.

The term “improved efficacy” or “improving efficacy” or “improvingtherapeutic efficacy” as used herein refers to the therapeuticallybeneficial effects of the topical active with reduction of systemicadverse effects as described in the present invention.

The term “therapeutic efficacy” as used herein means converting asubject with “very severe or severe” or “moderate conditions” to “mild”or “minimal or almost clear” or “clear” lesions in the scheduledtreatment period and this clinical determinations using InvestigatorGlobal Assessment (IGA) scoring method or by vasocontrictor assay (VCA)method (skin blanching assay) for corticosteroids or any suitable methodof accessing corticosteroids activity in skin. In some embodiments, theterm subject refers to a patient suffering from skin disorders such aspsoriasis. In some embodiments, the term “subject” refers to a patientinvolving psoriasis of at least about 5% body surface area or a patientinvolving psoriasis of at least about 10% body surface area or a patientinvolving psoriasis of more than about 10% body surface area.

The term “enhanced flux” as used herein refers to increase in the skinpermeation of the active in skin layers of the subject up to dermis withless systemic exposure. i.e., enhanced flux allows to utilize lower doseof active to treat disease condition effectively.

The term “penetration enhancing agent(s)” as used herein means compoundsthat enhance the penetration rate of a corticosteroid through the skinor mucous membrane, such as by temporarily diminishing theimpermeability of the skin or mucous membrane.

Generally, a penetration enhancing agent is a component used to enhancethe penetration rate of steroid through the skin or mucous membrane,such as by temporarily diminishing the impermeability of the skin ormembrane. Penetration enhancing agents are also been known as“accelerants” and “absorption promoters.”

Examples of suitable penetration enhancing agents include, but are notlimited to, polyols, glycols (except propylene glycol), ethers, glycolethers, esters, sulfoxides, fatty acids, fatty acid esters, fattyalcohols, essential oils, terpenes, terpenoids, PEGylated fatty acids,PEGylated fatty acid esters, PEGylated fatty alcohols and mixturesthereof, including polyethylene glycol, polyethylene glycol monolaurate,and butanediol; sulfoxides, including dimethylsulfoxide anddecylmethylsulfoxide; ethers, including diethylene glycol monoethylether and diethylene glycol monomethyl ether; fatty acids, includinglauric acid, oleic acid, and valeric acid; fatty acid esters, includingisopropyl myristate, isopropyl palmitate, methyl propionate, and ethyloleate; nitrogenous compounds including urea, dimethyl acetamide,dimethylformamide 2-pyrrolidone, ethanolamine, methyl-2-pyrrolidone,diethanolamine, and triethanolamine; terpenes; terpenoids; alkanones;organic acids, including salicylic acid, citric acid, and succinic acid;and combinations comprising one or more of the foregoing materials. Insome embodiments, the penetration enhancing agent used in thepharmaceutical composition of the present invention is diethylene glycolmonoethyl ether. In some embodiments, the penetration enhancing agent isnot polypropylene glycol. The penetration enhancing agent(s) mayinterchangeably be used as solvent.

The term “localized region,” as used herein refers to a discretelocation on the body surface of the subject, such as a locationexperiencing a symptom of condition being treated. As used herein, theterm “subject” includes both human and animal subjects. Thus, veterinarytherapeutic uses, as well as uses in connection with human subjects, areprovided in accordance with the present invention.

As used herein, the terms “treatment” or “treating” relate to curing orsubstantially curing a condition, as well as ameliorating at least onesymptom of the condition, and are inclusive of prophylactic treatmentand therapeutic treatment. As would be recognized by one or ordinaryskill in the art, treatment that is administered prior to clinicalmanifestation of a condition then the treatment is prophylactic (i.e.,it protects the subject against developing the condition). If thetreatment is administered after manifestation of the condition, thetreatment is therapeutic (i.e., it is intended to diminish, ameliorate,control, or maintain the existing condition and/or side effectsassociated with the condition). The terms relate to medical managementof a subject with the intent to substantially cure, ameliorate,stabilize, or substantially prevent a condition, including but notlimited to prophylactic treatment to preclude, avert, obviate,forestall, stop, or hinder something from happening, or reduce theseverity of something happening, especially by advance action. As such,the terms treatment or treating include, but are not limited to:inhibiting the progression of a condition of interest; arresting orpreventing the development of a condition of interest; reducing theseverity of a condition of interest; ameliorating or relieving symptomsassociated with a condition of interest; causing a regression of thecondition of interest or one or more of the symptoms associated with thecondition of interest; and preventing a condition of interest or thedevelopment of a condition of interest.

The present invention includes a topical composition including acorticosteroid. In some embodiments, the present invention provides atopical pharmaceutical composition comprising at least onecorticosteroid and at least one penetration enhancing agent. Thecomposition of the present invention is substantially free of propyleneglycol. In some embodiments, the composition includes not more than 10,9, 8, 7, 6, 5, 4, 3, 2, or 1% by weight of the total composition.

Thus, in some embodiments, the composition is substantially free ofpolypropylene glycol where there is less than 1% by weight polypropyleneglycol in the total composition. In other embodiments, the compositionis substantially free of polypropylene glycol where there is less than2, 3, 4, 5, 6, 7, 8, 9, or 10% by weight polypropylene glycol in thetotal composition. In other embodiments, the composition issubstantially free of polypropylene glycol where there is less thanabout 0% by weight polypropylene in the total composition.

In some embodiments, the present invention provides a topicalpharmaceutical composition comprising therapeutically effective amountof clobetasol propionate, at least one penetration enhancing agent andat least one pharmaceutically acceptable excipient, wherein thecomposition is substantially free of propylene glycol. In someembodiments, the present invention provides a method to provide anenhanced flux of clobetasol propionate through the localized region ofthe body surface to reach the dermis layer, comprising administering toan individual the effective amount of topical pharmaceutical compositioncomprising: (a) low dose of clobetasol propionate, (b) an oil phasecomprising: at least one penetration enhancing agent and a non-polymericthickening agent, (c) an aqueous phase; and (d) optionally, at least onepharmaceutically acceptable excipient; wherein the composition issubstantially free of propylene glycol and substantially free ofpolymers.

In some embodiments, the composition of the present application providescomparable or enhanced efficacy over the commercially availableclobetasol propionate 0.05% (w/w) cream composition (TEMOVATE E® cream)and does not show significant adverse effect on endocrine system asdescribed herein and as known to those of ordinary skill in the art.

Topical corticosteroids provide adverse effect on human endocrinesystem. High potent corticosteroids show high incidence of systemic sideeffects such as suppression of hypothalamus-pituitary-adrenal (HPA) axisthis effect is reversible. Topical corticosteroids are absorbedsystematically and show suppression of HPA axis. The HPA axissuppression is critical safety issue in topical corticosteroid therapy.The HPA axis suppression is generally evaluated by certain parameterssuch as levels of cortisol and levels of dehydroepiandrosterone (DHEA)and dehydroepiandrosterone sulfate (DHEAS) in a subject's blood duringtreatment schedule. The cortisol levels are determined by ACTH(cosyntropin) stimulation test. The ACTH stimulation test measures howthe adrenal glands respond to adrenocorticotropic hormone (ACTH). ACTHis a hormone produced in the pituitary gland that stimulates the adrenalglands to release a hormone called cortisol. The man-made form of ACTHis called cosyntropin. The normal level of cortisol is less than 18mcg/dL in a normal subject and cortisol level goes higher than 18 to 20micrograms per deciliter (mcg/dL) after ACTH injection to the subjectand similarly DHEA/DHEAS levels also changes in a subject who undergotreatment with topical corticosteroids, generally the standard referencerange of DHEA is 280-640 μg/dL in men and 65-380 μg/dL is in women.

Clobetasol propionate is a highly potent topical corticosteroid, whichis known to have effect on endocrine system which suppresses the HPAaxis at doses as low as 2 grams per day. Shortcomings of thepreviously-described therapy include necessity of periodic evaluationfor HPA axis suppression and modification in dosing and administratingschedule due to the HPA axis suppression.

Distinctly, the topical composition of the present invention does notshow significant adverse effect on endocrine system, when applied twicedaily for 15 days (2 weeks) in the subjects having affected body surfacearea of at least 20% up to 50% excluding face, scalp, groin, axillae andother intertriginous areas.

In some embodiments, the topical composition of the present inventioncomprises a therapeutically effective amount of clobetasol; an oil phasecomprising at least one skin penetration enhancer; an aqueous phase andoptionally one pharmaceutically acceptable excipient.

In some embodiments, the present invention provides a method forprophylaxis, amelioration, or treatment of psoriasis, relief of theinflammatory and pruritic manifestations of steroid responsivedermatoses, erythema, contact sensitivity reactions, and otherassociated diseases or disorders, by administering to an individual theeffective amount of topical composition comprising:

(a) a low dose of clobetasol propionate,

(b) an oil phase comprising: at least one penetration enhancing agentand a non-polymeric thickening agent,

(c) an aqueous phase; and

(d) optionally, at least one pharmaceutically acceptable excipient;wherein the composition is substantially free of propylene glycol andsubstantially free of polymers.

In some embodiments, the clobetasol present in the composition amountsfrom about 0.005% to about 0.1% of the total weight of the composition.In some embodiments, the clobetasol propionate is present in amountsfrom about 0.005% to about 0.05% of the composition, or in amounts up toabout 0.025% of the total weight of the composition.

In some embodiments of the present invention, the clobetasol propionateis present in amounts up to about 0.005, 0.006, 0.007, 0.008, 0.009,0.010, 0.011, 0.012, 0.013, 0.014, 0.015, 0.016, 0.017, 0.018, 0.019,0.020, 0.021, 0.022, 0.023, 0.024, 0.025, 0.026, 0.027, 0.028, 0.029,0.030, 0.031, 0.032, 0.033, 0.034, 0.035, 0.036, 0.037, 0.038, 0.039,0.040, 0.041, 0.042, 0.043, 0.044, or 0.045% of the total weight of thecomposition. In some embodiments, the clobetasol propionate is presentin amounts of less than 0.0500% of the total weight of the composition.In some embodiments, the clobetasol propionate is present in amounts ofabout 0.010 to about 0.040% of the total weight of the composition. Insome embodiments, the clobetasol propionate is present in amounts ofabout 0.015 to about 0.035% of the total weight of the composition. Insome embodiments, the clobetasol propionate is present in amounts ofabout 0.020 to about 0.030% of the total weight of the composition.

In other embodiments, the composition of the present invention comprisesat least one penetration enhancing agent in an amount of from about 1%to about 30.0% of the weight of the composition, or in amounts of fromabout 0.01% to about 10.0% of the composition. In some embodiments ofthe present invention, the at least one penetration enhancing agent isprovided in amounts up to about 0.05, 0.10, 0.15, 0.20, 0.25, 0.30,0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90,0.95, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0,7.5, 8.0, 8.5, 9.0, 9.5, or 10% of the weight of the composition.

In another embodiment, the present invention provides a topicalpharmaceutical composition comprising: a low dose of clobetasolpropionate in an amount selected from about 0.005% to about 0.1% of thetotal weight of the composition; an oil phase comprising at least onepenetration enhancing agent in an amount from about 0.01% to about 15.0%of the total weight of the composition and a non-polymeric thickeningagent, an aqueous phase, and optionally, at least one pharmaceuticallyacceptable excipient, wherein the composition is substantially free ofpropylene glycol and substantially free of polymers.

In yet another embodiment, the present invention provides a method forprophylaxis, amelioration or treatment of skin diseases or disorderssuch as psoriasis/psoriatic plaques, relief of the inflammatory andpruritic manifestations of steroid responsive dermatoses, erythema,contact sensitivity reactions, atopic dermatitis, seborrhoeicdermatitis, eczema, plaque psoriasis, erythrodermic psoriasis, psoriasisof the scalp, and other associated diseases or disorders, byadministering to an individual an effective amount of a topicalcomposition comprising: (a) clobetasol propionate in an amount of about0.025% of the total weight of the composition, (b) an oil phasecomprising: at least one penetration enhancing agent and a non-polymericthickening agent, (c) an aqueous phase, and (d) at least onepharmaceutically acceptable excipient, wherein the composition issubstantially free of propylene glycol and the composition hascomparable or improved efficacy compared to the commercially availableclobetasol propionate 0.05% (w/w) cream composition (TEMOVATE® cream).In some embodiments, the topical composition is administered twice-a-dayfor a period of 4 weeks or topical composition is administeredtwice-a-day for a period of at least 2 weeks.

In another embodiment, the penetration enhancing agent used in thepresent invention is selected from the group consisting of polyols,glycols (except propylene glycol), ethers, glycol ethers, esters,sulfoxides, fatty acids, fatty acid esters, fatty alcohols, essentialoils, terpenes, terpenoids, PEGylated fatty acids, PEGylated fatty acidesters, PEGylated fatty alcohols, and mixtures thereof.

In other embodiments of the present invention, the penetration enhancingagent is diethylene glycol monoethylether.

In some embodiments, a composition of the present invention comprisesone or more additional active agents that are useful in the managementof psoriasis and associated pathological conditions including synthetic,semi-synthetic, or naturally obtained active agents.

The composition of the present invention can be used for prophylaxis,amelioration, or treatment of skin diseases and disorders, byadministering a pharmaceutically effective amount of the composition toa subject in need thereof. The compositions of the present invention arealso useful in conjunction with other therapies, such as phototherapy.

In other embodiments, the present invention provides a process forpreparing a topical pharmaceutical composition, comprising:

(i) preparing an oil phase by melting and stirring thickening agent(s),emulsifier(s) followed by preservative(s) and emollient(s);

(ii) preparing an aqueous phase by heating water,

(iii) preparing an emulsion by adding the oil phase of step (i) to theaqueous phase of step (ii) or vice versa under constant homogenization,

(iv) dissolving a premixed solution of clobetasol in a solvent followedby addition of an antioxidant(s) and homogenizing to obtain a clobetasolsolution, and

(v) adding the clobetasol solution obtained in step (iv) to the emulsionprepared in step (iii) followed by homogenization and cooling to obtaina cream composition.

In still further embodiments, the present invention provides a processfor preparing topical pharmaceutical composition comprising:

(i) preparing an oil phase by melting and stirring stearyl alcohol,cetyl alcohol, whitewax; glyceryl stearate and PEG 100 stearate andemollient, followed by methyl paraben and propyl paraben, and theremaining part of the mineral oil,

(ii) preparing an aqueous phase by adding sorbitol solution into heatedwater,

(iii) preparing an emulsion by adding the oil phase of step (i) to theaqueous phase (ii) or vice versa under homogenization,

dissolving a premixed solution of clobetasol propionate in a diethyleneglycol monoethyl ether and the followed by addition of BHT andhomogenizing to obtain a clobetasol propionate solution, and

(iv) adding the steroid solution obtained in step (iv) to the emulsionprepared in step (iii) followed by homogenization to obtain a creamcomposition.

In further embodiments, the compositions of the present invention usingone or more other corticosteroids can be prepared by using a processsimilar to that described above.

The topical pharmaceutical composition of the present invention isuseful in the prophylaxis, amelioration or treatment of skin diseases ordisorders such as psoriasis/psoriatic plaques, relief of theinflammatory and pruritic manifestations of steroid responsivedermatoses, erythema, contact sensitivity reactions, atopic dermatitis,seborrhoeic dermatitis, eczema, plaque psoriasis, erythrodermicpsoriasis, psoriasis of the scalp, and other associated diseases ordisorders.

In some embodiments of the present invention, it was surprisingly foundthat the topical compositions of the invention containing an oil phasethat comprises at least one penetration enhancing agent, and an aqueousphase, provides an enhanced flux of clobetasol through the localizedregion of the body surface to reach the dermis layer; thisadvantageously allows for the use of a lower concentration ofclobetasol, i.e., about 50% less than the commercially available dosageform TEMOVATE® cream (which contains 0.05% (w/w) of clobetasolpropionate), while providing a similar or improved efficacy and providesno significant effect on endocrine system i.e., HPA axis suppression.

In still further embodiments of the invention, it has now been foundthat the pharmaceutical composition of the present invention containing3% of penetration enhancing agent provides similar or improved efficacyas compared to TEMOVATE® cream (which contains 0.05% (w/w) of clobetasolpropionate). In further embodiments of the invention, the pharmaceuticalcomposition of the present invention containing 10% of penetrationenhancing agent.

Further, it is observed that the topical pharmaceutical composition ofthe present invention, which is free of propylene glycol, isnon-irritating, non-toxic, and well-tolerated and are free of anyundesired attributes, thereby providing a high degree of patientcompliance.

In other embodiments, compositions of the present application presentinvention are physically and chemically stable.

In other embodiments, topical pharmaceutical compositions of the presentinvention are useful in the relief of the inflammatory and pruriticmanifestations of steroid responsive dermatoses, and further can providea moisturizing and/or soothing effect at the site of application to theskin. The composition of the application reduces the dryness thataccompanies the build-up of skin in psoriatic plaques.

In other embodiments, the composition of the application can be applieddirectly to the psoriatic lesions or dermatoses and can help reduceinflammation, remove built-up scale, reduce skin turnover, and/or clearaffected skin of plaques.

In some embodiment, the compositions of the present invention canutilize any topical corticosteroids, either alone or in combination ofothers. Suitable examples of topical corticosteroids include, but notlimited to, clobetasol propionate, alclometasone dipropionate,amcinonide, beclomethasone dipropionate, betamethasone benzoate,betamethasone dipropionate, betamethasone sodium phosphate,betamethasone valerate, budesonide, clocortolone pivalate, desonide,desoximetasone, dexamethasone, dexamethasone acetate, dexamethasonenicotinate, dexamethasone propionate, dexamethasone sodium phosphate,dexamethasone valerate, diflorasone diacetate, diflucortolone valerate,fluandrenolide, flumethasone pivalate, fluocinolone acetonide,fluocinonide, fluocortin butyl ester, fluticasone propionate,halcinonide, halobetasol propionate, halometasone monohydrate,hydrocortisone, hydrocortisone sodium phosphate, hydrocortisone sodiumsuccinate, hydrocortisone-17-butyrate-21-propionate, hydrocortisoneaceponate, hydrocortisone acetate, hydrcortisone valerate,hydrocortisone butyrate, hydrocortisone probutate, methylprednisolone,methylprednisolone acetate, methylprednisolone aceponate, mometasonefuroate, prednisolone, prednisolone sodium phosphate, prednisoloneacetate, prednisolone-17-valerate-21-acetate, triamcinolone acetonide,triamcinolone acetate, triamcinolone diacetate, and prednicarbate. Otherdrug compounds are also useful, and this application furtherspecifically contemplates the use of any combinations of steroid drugs.

The topical compositions of the present invention may be in the form ofsolution, suspension, emulsions, creams, ointments, lotions,microemulsions, nanoemulsions, emulgels, liposomes, micelle, reversemicelle, gels, hydrogels, sprays and the like.

In an embodiment, the topical composition of the present invention maybe in form of compositions, comprising two phases: an oil phase and anaqueous phase and compositions of the present invention may be in theform of emulsions, creams, lotions, microemulsions, nanoemulsions,emulgels, liposomes, micelles, reverse micelle, spray and the like. Insome embodiments, compositions may be in the form of an emulsion. Theemulsion can be in the form of an oil-in-water type of emulsion or awater-in-oil type of emulsion. An aqueous-based emulsion, such as anoil-in-water emulsion, frequently has lower viscosity than otheremulsion types and exhibits appreciable storage stability and patientcompliance. Generally, oil-in-water emulsions have better skin feelproperties, when applied to the skin, as these give sensations similarto an aqueous material.

In some embodiments, pharmaceutical compositions of the presentinvention are formulated as emulsions, comprising an oily or hydrophobicphase, an aqueous or hydrophilic phase, and an emulsifier. When the oilyphase is dispersed as droplets within an aqueous continuous phase, thisis called an “oil-in-water” type of emulsion. When the aqueous phase isdispersed as droplets within an oily continuous phase, this is called a“water-in-oil” type of emulsion.

In some embodiments, a pharmaceutical composition of the presentinvention is aqueous-based topical oil-in-water emulsion. The“aqueous-based” term is defined as an emulsion which comprises highpercentage of water. The aqueous-based oil-in-water emulsion compositionof the present invention comprises at least 60%/o of water in the finalcomposition, or comprises at least 70% of water in the finalcomposition.

In some embodiments, an aqueous-based topical oil-in-water emulsioncomposition of the present invention comprises: a therapeuticallyeffective amount of a corticosteroid and at least one pharmaceuticallyacceptable excipient, wherein the composition is substantially free ofpropylene glycol and substantially free of polymers.

In some embodiments, an aqueous-based topical oil-in-water emulsioncomposition of the present invention comprises: (a) a therapeuticallyacceptable amount of clobetasol (b) a discontinuous oil phasecomprising: a solvent and at least one penetration enhancing agent; (c)a continuous aqueous phase; and (d) at least one pharmaceuticallyacceptable excipient, wherein the composition is substantially free ofpropylene glycol and substantially free of polymers. In someembodiments, the topical composition comprises: (a) a therapeuticallyacceptable amount of clobetasol of about 0.025% (w/w); (b) an oil phasecomprising: at least one penetration enhancing agent, and anon-polymeric thickening agent; (c) an aqueous phase; and (d) optionallyone pharmaceutically acceptable excipient; wherein the said topicalcomposition is substantially free of propylene glycol and substantiallyfree of polymers; wherein the topical composition provides nosignificant adverse effect on endocrine system.

In further embodiments, an aqueous based topical oil-in-water emulsioncomposition of the present invention has viscosity in the range of fromabout 10 cP to about 100000 cP. The viscosities of the aqueous-basedemulsion compositions of the present invention may be in the range ofabout 0.01-100 Pascal second, “Pa·s” (10-1,00,000 cP), or about 0.1 to100 Pa·s (100-1,00,000 cP) or about 1-50 Pa·s (1000-50,000 cP), or about0.01-15 Pa·s (10-15,000 centipoise, “cP”), or about 0.02-1.5 Pa·s(20-1,500 cP), or about 0.05-1 Pa·s (50-1,000 cP).

The viscosity of topical compositions of the present invention is in therange of from about 0.1 cP to about 500 cP when measured by Brookfieldviscometer Cap 2000+ with spindle no. 1 at 530 rpm at 25° C.

In another embodiment, pharmaceutical composition of the presentinvention includes one or more pharmaceutically acceptable excipient,which may act as carrier(s), emulsifier(s), co-emulsifier(s) solvent(s),co-solvents(s), emollient(s), antioxidant(s), preservative(s), gellingor thickening agent(s), polymer(s), surfactant(s), soothing agent(s), pHmodifier(s), solubilizer(s), humectants(s), moisturizer(s), oilybase(s), and the like.

The term ‘carrier’ or “vehicle” denotes organic or inorganicingredients, natural or synthetic, with which an active ingredient iscombined to facilitate application of a composition. Examples ofcarriers include, but not limited to, water, acetone, alone or incombination with materials such as silicone fluids. In certainembodiments, the carrier can comprise, in addition to water,water-immiscible substances such as any pharmaceutically acceptablefatty esters of natural fatty acids, triglycerides of animal orvegetable, medium chain triglycerides, mixtures of mono-, di- and/ortriglycerides, waxes, hydrogenated vegetable oils, and mixtures thereof.

Examples of emulsifying agents include, but not limited to, disodiumcocoampho diacetate, oxyethylenated glyceryl cocoate (7 EO), PEG-20hexadecenyl succinate, PEG-15 stearyl ether, ricinoleic monoethanolamidemonosulfosuccinate salts, oxyethylenated hydrogenated ricinoleictriglyceride containing 60 ethylene oxide units such as the productsmarketed by BASF under the trademarks CREMOPHOR® RH 60 or CREMOPHOr® RH40 (polyoxyl 40 hydrogenated castor oil), polymers such as poloxamers,which are block copolymers of ethylene oxide and propylene oxide, andthe nonsolid fatty substances at room temperature (that is to say, attemperatures ranging from about 20 to 35° C.) such as sesame oil, sweetalmond oil, apricot stone oil, sunflower oil, octoxyglyceryl palmitate(or 2-ethylhexyl glyceryl ether palmitate), octoxyglyceryl behenate (or2-ethylhexyl glyceryl ether behenate), dioctyl adipate, and tartrates ofbranched dialcohols. Sorbitan fatty acid esters are a series of mixturesof partial esters of sorbitol and its mono- and dianhydrides with fattyacids. Sorbitan esters include products marketed as ARLACEL® 20, ARLACEL40, ARLACEL 60, ARLACEL 80, ARLACEL83, ARLACEL 85, ARLACEL 987, ARLACELC, PEG-6 stearate and glycol stearate and PEG-32 stearate (TEFOSE® 63),and PEG-6 stearate and PEG-32 stearate (TEFOSE® 1500), glyceryl stearateand PEG 100 stearate (TEFOSE® 165) and any mixtures thereof.Polyethylene glycol ethers of stearic acid are in another group ofemulsifiers that can be used in the emulsions. Examples of polyethyleneglycol ethers of stearic acid include, but not limited to, steareth-2,steareth-4, steareth-6, steareth-7, steareth-10, steareth-11,steareth-13, steareth-15, steareth-20, polyethylene glycol ethers ofstearyl alcohol (steareth 21), and any mixtures thereof. Otheremulsifying agents include sodium lauryl sulphate, cetyl trialkylammonium bromide, polyoxyethylene sorbitan fatty acid esters, and anymixtures thereof

Nonionic emulsifying agents include those that can be broadly defined ascondensation products of long chain alcohols, e.g., C₈₋₃₀ alcohols, withsugar or starch polymers, i.e., glycosides. Various sugars include, butnot limited to, glucose, fructose, mannose, and galactose, and variouslong chain alcohols include, but are not limited to, decyl alcohol,cetyl alcohol, stearyl alcohol, lauryl alcohol, myristyl alcohol, oleylalcohol, and any mixtures thereof.

Other useful nonionic emulsifying agents include condensation productsof alkylene oxides with fatty acids such as alkylene oxide esters offatty acids. Other nonionic surfactants are the condensation products ofalkylene oxides with 2 moles of fatty acids such as alkylene oxidediesters of fatty acids.

Emulsifying agents can also include any of a wide variety of cationic,anionic, zwitterionic, and amphoteric surfactants that are known in theart. Examples of anionic emulsifying agents include, but not limited to,alkyl isethionates, alkyl and alkyl ether sulfates and salts thereof,alkyl and alkenyl ether phosphates and salts thereof, alkyl methyltaurates, and soaps (e.g., alkali metal salts and sodium or potassiumsalts) of fatty acids.

Examples of amphoteric and zwitterionic emulsifying agents include thosewhich are broadly described as derivatives of aliphatic secondary andtertiary amines in which the aliphatic radical can be straight orbranched chain, wherein one of the aliphatic substituents contains fromabout 8 to about 22 carbon atoms and one contains an anionic watersolubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, orphosphonate. Specific examples include, but not limited to, alkyliminoacetates, iminodialkanoates and aminoalkanoates, imidazolinium andammonium derivatives. Other suitable amphoteric and zwitterionicemulsifying agents include betaines, sultaines, hydroxysultaines, alkylsarcosinates, and alkanoyl sarcosinates.

Silicone emulsifying agents are typically organically modifiedorganopoly siloxanes, sometimes called silicone surfactants. Usefulsilicone emulsifying agents include dimethicone copolyols. Thesematerials are polydimethyl siloxanes, which have been modified toinclude polyether side chains such as polyethylene oxide chains,polypropylene oxide chains, mixtures of these chains, and polyetherchains containing moieties derived from both ethylene oxide andpropylene oxide.

Co-emulsifiers or secondary emulsifying agents include, but not limitedto, polyoxylglycerides such as oleoyl macrogolglycerides (LABRAFIL® M1944CS), linoleoyl macrogolglycerides (LABRAFIL® M 2125CS),caprylocaproyl macrogolglycerides (LABRASOL®), cetyl alcohol (and)ceteth-20 (and) steareth-20 (EMULCIRE™ 61 WL 2659), glyceryl stearate(and) PEG-75 stearate (GELOT® 64), d-alpha tocopheryl polyethyleneglycol 1000 succinate (TPGS) and any mixtures thereof.

The term “solvent” refers to components that aid in the dissolution ofthe drug in the formulation. Solvents serve to maintain a solution ofthe drug in the composition. Some solvents can also enhance percutaneouspenetration of drug and/or act as humectants. For topicalcorticosteroids, solvents can include water-immiscible substances suchas fatty esters of natural fatty acids, triglycerides of animal orvegetable, medium chain triglycerides, mixtures of mono-, di- and/ortriglycerides, waxes, hydrogenated vegetable oils, and mixtures thereof.Some specific examples include, but not limited to, castor oil,isopropyl myristate, dimethyl isosorbide, oleyl alcohol, labrafil,labrasol, medium chain triglyceride, diethyl sebacate, lanolin oil,citrate triisocetyl triglycerides having 10-18 carbon atoms,caprylic/capric triglycerides, coconut oil, corn oil, cottonseed oil,linseed oil, oil of mink, olive oil, palm oil, sunflower oil, nut oil,saturated paraffin oils, mineral oils, vegetable oils or glycerides, andthe like. Solvent can also be selected from the group comprisingmonoalkyl ether of diethylene glycol such as diethylene glycolmonomethyl ether, diethylene glycol monoethyl ether or mixtures thereof.In some embodiments, the solvent is diethylene glycol monoethyl ether.It is marketed by Gattefosse under the trade name TRANSCUTOL®,TRANSCUTOL-P®, TRANSCUTOL-CG®, and TRANSCUTOL-HP®.

In an embodiment, a solvent is selected from the group consisting of:mineral oil, isopropyl myristate, dimethyl isosorbide, oleyl Alcohol,labrafil, labrasol, medium chain triglyceride, diethyl sebacate,ammonium lauryl sulfate, lauramine oxide, sodium laureth sulfate,n-methyl-2-pyrrolidinone, octanoic_acid, cocobetaine, dimethylsulfoxide,sodium laureth 2 sulfate, benzyl_alcohol, ethylacetate, lactic acid,oleic acid, ethylacetate, spearmint oil, isostearic acid, ethanol,propylene glycol diacetate, dimethyl isosorbide, 1-butanol, methylgluceth-10, sodium lauroylsarcosinate, polysorbate 20, isopropylalcohol, 1-butanol, Capryol 90, sorbitanmonooleate, glycerylricinoleate, poloxamer, polyethylene glycol 200, polysorbate 65,triacetin, benzylalcohol, castor oil, arlacel 165, propylene glycolricinoleate, glyceryl isostearate, propylene glycol, diethyl phthalate,glyceryl oleate, PEG-8 laurate, sorbitan sesquioleate, PPG-26 oleate,1-octanol, Lauroglycol_FCC, diisopropyladipate, laureth 4, and diethylsebacate. for solubilizing clobetasol propionate. The compositions ofthe present invention comprising from about 1% (w/w) to 30% (w/w) ofsolvent based on total weight of the composition.

The term “emollients” are substances that soften and soothe the skin.They are used to prevent dryness and scaling of the skin. Examples ofemollients that can be used in the present invention include, but notlimited to, oils of natural origin such as almond oil, coconut oil,olive oil, palm oil, peanut oil and the like, fatty acids such as lauricacid, myristic acid, palmitic acid, and stearic acid, monohydric alcoholesters of the fatty acids such as ethyl laurate, isopropyl laurate,ethyl myristate, n-propyl myristate, isopropyl myristate, ethylpalmitate, isopropyl palmitate, methyl palmitate, methyl stearate, ethylstearate, isopropyl stearate, butyl stearate, isobutyl stearate, amylstearate, and isoamyl stearate, glycols such as ethylene glycol,diethylene glycol, polyethylene glycol, branched aliphatic alcohols suchas lauryl alcohol, myristyl alcohol, and stearyl alcohol, or mixturesthereof. Exemplary emollients include caprylic/capric triglyerides,castor oil, ceteareth-20, ceteareth-30, cetearyl alcohol, ceteth 20,cetostearyl alcohol, cetyl alcohol, cetyl stearyl alcohol, cocoa butter,diisopropyl adipate, glycerin, glyceryl monooleate, glycerylmonostearate, glyceryl stearate, isopropyl myristate, isopropylpalmitate, lanolin, lanolin alcohol, hydrogenated lanolin, liquidparaffins, linoleic acid, mineral oil, oleic acid, white petrolatum,polyethylene glycol, polyoxyethylene glycol fatty alcohol ethers,silicones and mixtures thereof.

Silicones are typically organically modified organopoly siloxanes,sometimes called silicone surfactants. Useful polysiloxane or siliconeemollients include, but not limited to, polysiloxane polymer,dimethicone copolyols, cyclomethicones. These materials are polydimethylsiloxanes, which have been modified to include polyether side chainssuch as polyethylene oxide chains, polypropylene oxide chains, mixturesof these chains, and polyether chains containing moieties derived fromboth ethylene oxide and propylene oxide.

The term “antioxidants” are substances which inhibit oxidation orsuppress reactions promoted by oxygen or peroxides. Antioxidants,especially lipid-soluble antioxidants, can be absorbed into the cellularmembrane to neutralize oxygen radicals and thereby protect the membrane.Suitable antioxdants that can be used in the present invention include,but not limited to, ascorbic acid (vitamin C), glutathione, lipoic acid,uric acid, sorbic acid, carotenes, α-tocopherol (vitamin E), TPGS,ubiquinol, butylated hydroxyanisole, butylated hydroxytoluene, sodiumbenzoate, propyl gallate (PG, E310), and tertiary-butylhydroquinone.

The term “preservative” refers to a natural or synthetic chemical thatprevents the decomposition of the composition by microbial growth or byundesirable chemical changes. Preservatives can desirably beincorporated into a composition for protecting against the growth ofpotentially harmful microorganisms. While microorganisms tend to grow inan aqueous phase and can also reside in a hydrophobic or oil phase.Examples of preservatives that can be used in the present inventioninclude, but not limited to, methylparaben, propylparaben, benzylalcohol, chlorocresol, benzalkonium chloride, cetrimonium chloride,sodium edetate, boric acid, sorbic acid, or any mixtures thereof.

The term “thickening agents” or “gelling agents” are used to givebulkiness to the composition. Examples of thickening agents or gellingagents that can be used in the present invention include, but notlimited to carbomers, polyethylene glycols, acrylate polymers,methacrylate polymers, polyvinylpyrrolidones, copolymers based on butylmethacrylate and methyl methacrylate povidone, vinyl acetates, polyvinylacetates, celluloses, gums, alginates, cellulose acetate phthalates,cellulose acetate butyrates, hydroxypropyl methyl cellulose phthalates,and the like. Examples include CARBOPOL® products, PEG 400, EUDRAGIT®100, EUDRAGIT® RSPO, EUDRAGIT® RLPO, EUDRAGIT® ND40, PLASDONE®,copolymers based on butyl methacrylate and methyl methacrylate(PLASTOID® B), alkyl celluloses such as ethyl celluloses and methylcelluloses, hydroxyalkyl celluloses such as hydroxyethyl cellulose andhydroxypropyl cellulose, hydroxyalkyl alkyl celluloses such ashydroxypropyl methyl celluloses and hydroxybutyl methyl celluloses, gumssuch as xanthan gum, tragacanth, guar gum, locust bean gum, acacia, andthe like.

In an embodiment, the thickening agents are non-polymeric thickeningagents, examples of non-polymeric thickening agent are fatty alcoholselected from group comprising: cetyl alcohol, paraffin, stearylalcohol, white wax, wax cetyl esters, microcrystalline wax, anionicemulsifying wax, nonionic emulsifying wax, yellow wax, castor oil,ceresin, cetostearyl alcohol, cyclomethicone, glyceryl behenate,hectorite, myristyl alcohol, cetylstearyl alcohol, triolein, andlanolin. Fatty alcohols that can be used as non-polymeric thickeningagent, include but not limited to stearyl alcohol, oleyl alcohol, cetylalcohol, cetostearyl alcohol are long chain fatty alcohols. StearylAlcohol is a white, waxy solid with a faint odor, while oleyl alcoholand octyl dodecanol are clear, colorless liquids. Oleyl alcohol is anunsaturated fatty alcohol, similar to the saturated fatty alcoholsstearyl alcohol and cetyl alcohol. In an embodiment, the topicalcompositions of the present invention are substantially free ofpolymers.

Other thickening agents or gelling agents or polymers that are useful inthe present invention include, but not limited to, polyamides,polycarbonates, polyalkylenes, polyalkylene glycols, polyalkyleneoxides, polyalkylene terepthalates, polyvinyl alcohols, polyvinylethers, polyvinyl esters, polyvinyl halides, polyglycolides,polysiloxanes, polyurethanes and copolymers thereof, cellulose ethers,cellulose esters, nitrocelluloses, polymers of acrylic and methacrylicesters, cellulose acetates, cellulose propionates, cellulose acetatebutyrates, cellulose acetate phthalates, carboxylethyl celluloses,cellulose triacetates, cellulose sulphate sodium salts, poly(methylethacrylate), poly(ethylmethacrylate), poly(butylmethacrylate),poly(isobutylmethacrylate), poly(hexylmethacrylate),poly(isodecylmethacrylate), poly(lauryl methacrylate), poly(phenylmethacrylate), poly(methyl acrylate), poly(isopropyl acrylate),poly(isobutyl acrylate), poly(octadecyl acrylate), polyethylenes,polypropylenes, poly(ethylene glycol), poly(ethylene oxide),poly(ethylene terephthalate), poly(vinyl alcohol), poly(vinyl acetate),poly(vinyl chloride), polystyrenes, and the like, including theirmixtures thereof.

Examples of other useful polymers that can act as thickening agents orgelling agents include, but not limited to, synthetic polymers, such aspolymers of lactic acid and glycolic acid, polyanhydrides, poly(orthoester), polyurethanes, poly(butyric acid), poly(valeric acid),poly(caprolactone), poly(hydroxybutyrate), poly(lactide-co-glycolide),poly(lactide-co-caprolactone), and natural polymers such as alginate andother polysaccharides that include but not limited to arabinans,fructans, fucans, galactans, galacturonans, glucans, mannans, xylans(such as, for example, inulin), levan, fucoidan, carrageenan,galactocarolose, pectic acid, pectin, amylose, pullulan, glycogen,amylopectin, cellulose, dextran, pustulan, chitin, agarose, keratan,chondroitan, dermatan, hyaluronic acid, alginic acid, xanthan gum,starches, and various other natural homopolymers and heteropolymers,such as those containing one or more of aldoses, ketoses, acids oramines, erythrose, threose, ribose, arabinose, xylose, lyxose, allose,altrose, glucose, mannose, gulose, idose, galactose, talose,erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose,mannitol, sorbitol, lactose, sucrose, trehalose, maltose, cellobiose,glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine,aspartic acid, glutamic acid, lysine, arginine, histidine, glucuronicacid, gluconic acid, glucaric acid, galacturonic acid, mannuronic acid,glucosamine, galactosamine, and neuraminic acid, and naturally occurringderivatives thereof, and including dextran and cellulose, collagen,albumin and other hydrophilic proteins, zein and other prolamines andhydrophobic proteins, copolymers and mixtures thereof.

The term “humectant” refers to a hygroscopic substance that is often amolecule with several hydrophilic groups, most often hydroxyl groups,but amines and carboxyl groups, sometimes esterified, can be encounteredas well; the affinity to form hydrogen bonds with molecules of water iscrucial here. Examples of humectants include, but not limited to,glycerol, and glyceryl triacetate (E1518). Others can be sugar polyolslike sorbitol (E420), xylitol and maltitol (E965), polymeric polyolslike polydextrose (E1200), or natural extracts like quillaia (E999),lactic acid or urea.

Some of the excipients described above can have more than one functionin a composition. For example, an excipient can be both a solvent and apenetration enhancer, or both a solvent and a carrier. Thecategorizations of excipients described above are not to be construed aslimiting or restricting in any manner.

The composition of the present application can be applied directly ontoaffected areas of the skin, such as psoriatic plaques or dermatoses.Cream compositions, are applied in the form of film on the affectedareas and, in embodiments, can provide release of the active agent foran extended duration of time.

In some embodiments, the topical composition of the present inventioncomprising: (a) a low dose of clobetasol; (b) an oil phase comprising:at least one penetration enhancing agent, and a non-polymeric thickeningagent; (c) an aqueous phase; and (d) optionally, at least onepharmaceutically acceptable excipient; wherein the said topicalcomposition comprising low dose of clobetasol has dose proportionaterelease rate as to be equivalent or more than the release rates ofTEMOVATE® 0.05% cream. The term dose proportionate release rate as usedherein means the topical composition of the present invention releasesclobetasol such that concentration of clobetasol is equivalent to ormore than the concentration delivered by 0.05% (w/w) topical clobetasolcompositions such as TEMOVATE® cream. The dose proportionate releaserate is cumulative percentage of drug release is at least about 6% ofapplied dose of clobetasol in about 9 hours.

In some embodiments, the topical composition of the present inventioncomprises a) a low-dose clobetasol; b) an oil phase comprising at leastone penetration enhancing agent, and a non-polymeric thickening agent;and c) an aqueous phase; wherein the said composition provides a similaror improved therapeutic effect as compared to the topical compositioncomprising highest approved topical dose of clobetasol i.e. TEMOVATE®.

In some embodiments, the topical composition of the present inventioncomprises a) a low-dose clobetasol; b) an oil-in-water emulsioncomprising a dispersed oil phase comprising at least one penetrationenhancing agent, and a non-polymeric thickening agent, and a continuousaqueous phase; and c) one or more pharmaceutically acceptableexcipients; wherein the said composition provides a similar or improvedtherapeutic effect as compared to the topical composition comprisinghighest approved topical dose of clobetasol i.e. TEMOVATE®.

In some embodiments, the topical composition of the present inventioncomprises low-dose clobetasol, wherein the composition provides asimilar or an improved therapeutic effect and reduced adverse effect ascompared to that of TEMOVATE®.

In some embodiments, the topical composition of the present inventioncomprises a low-dose clobetasol, wherein the composition provides asimilar or an improved therapeutic effect and reduced adverse effect ascompared to that of TEMOVATE®.

In some embodiments, the topical composition of the present inventioncomprises clobetasol provides lower percentage of reduction in serumconcentration of dehydroepiandrosterone sulfate (DHEAS) and provides asimilar or improved therapeutic effect as compared to that of TEMOVATE®.

In some embodiments, the topical composition of the present inventioncomprises a low-dose clobetasol, wherein the said composition provideslower percentage of reduction in serum concentration ofdehydroepiandrosterone sulfate (DHEAS) and provides a similar orimproved therapeutic effect as compared to that of TEMOVATE®.

In some embodiments, the topical composition of the present invention isoil-in-water emulsion or water-in-oil emulsion. In some embodiments, thetopical composition comprising clobetasol is oil-in-water emulsion. Insome embodiments, the topical composition is oil-in-water emulsioncomprising (a) a dispersed oil phase comprising at least one skinpenetration enhancing agent, a non-polymeric thickening agent and acontinuous aqueous phase; and (b) one or more pharmaceuticallyacceptable excipients.

In some embodiments, the low-dose clobetasol is present in an amountfrom about 0.005% to about 0.04% of the total weight of the composition.

In some embodiments, the low-dose clobetasol is present in an amountfrom about 0.005% to about 0.04% of the total weight of the composition.

In some embodiments, the low dose clobetasol is about 10% less than thehighest approved topical dose of clobetasol 0.05% (w/w), i.e. about0.04% (w/w) based on total weight of the composition.

In some embodiments, the low dose clobetasol is about 200/% less thanthe highest approved topical dose of clobetasol 0.05% (w/w), i.e. about0.04% (w/w) based on total weight of the composition.

In some embodiments, the low dose clobetasol is about 30% less than thehighest approved topical dose of clobetasol 0.05% (w/w), i.e. about0.035% (w/w) based on total weight of the composition.

In some embodiments, the low dose clobetasol is about 40%° less than thehighest approved topical dose of clobetasol 0.05% (w/w), i.e. about0.03% (w/w) based on total weight of the composition.

In some embodiments, the low dose clobetasol is about 500/% less thanthe highest approved topical dose of clobetasol 0.05% (w/w), i.e. about0.025% (w/w) based on total weight of the composition.

In some embodiments, the low dose clobetasol is about 60% less than thehighest approved topical dose of clobetasol 0.05% (w/w), i.e. about0.02% (w/w) based on total weight of the composition.

In some embodiments, the low dose clobetasol is about 70% less than thehighest approved topical dose of clobetasol 0.05% (w/w), i.e. about0.015% (w/w) based on total weight of the composition.

In some embodiments, the low dose clobetasol is about 80% less than thehighest approved topical dose of clobetasol 0.05% (w/w), i.e. about0.01% (w/w) based on total weight of the composition.

In some embodiments, the low dose clobetasol is about 90% less than thehighest approved topical dose of clobetasol 0.05% (w/w), i.e. about0.005% (w/w) based on total weight of the composition.

In a preferred aspect, the low-dose clobetasol is about 50% less thanthe highest approved topical dose of clobetasol 0.05%, i.e. about 0.025%(w/w) based on total weight of the composition.

In some embodiments, the topical composition comprises a low doseclobetasol of about 0.025% (w/w) provides equivalent therapeuticefficacy of highest approved topical dose of clobetasol of 0.05% (w/w).

In some aspects of the present invention, the clobetasol is clobetasolpropionate i.e. clobetasol-17-propionate.

In some aspects of the present invention, the clobetasol is clobetasolpropionate i.e. clobetasol-17-propionate and the clobetasol propionateconcentration is in the amount of about 0.025% (w/w).

In some embodiments, the topical composition of the present inventionprovides a similar or improved therapeutic efficacy and/or reducedadverse effect of clobetasol. In some embodiments, the topicalcomposition of the present invention provides a similar or improvedtherapeutic efficacy and/or reduced adverse effect of clobetasolpropionate.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) of clobetasol; b) an oil phasecomprising at least one penetration enhancing agent, and a non-polymericthickening agent; and c) an aqueous phase; wherein the said compositionprovides a similar or improved therapeutic effect as compared to that ofthe topical composition comprising highest approved topical dose ofclobetasol i.e. TEMOVATE®.

In some embodiments, the topical cream composition of the presentinvention comprises a) about 0.025% (w/w) of clobetasol propionate; b)an oil phase comprising at least one penetration enhancing agent, and anon-polymeric thickening agent; and c) an aqueous phase; wherein thesaid composition provides a similar or improved therapeutic effect ascompared to that of the topical composition comprising highest approvedtopical dose of clobetasol i.e. TEMOVATE® cream.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) of clobetasol; b) an oil phasecomprising at least one penetration enhancing agent, and a non-polymericthickening agent; and c) an aqueous phase; wherein the said compositionprovides a similar or improved therapeutic effect as compared to that ofthe topical composition comprising highest approved topical dose ofclobetasol i.e. TEMOVATE® and the said composition provides meanclobetasol plasma concentrations less than about 130 pg/mL. In anotherembodiment TEMOVATE® is TEMOVATE® cream.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) of clobetasol propionate; b) an oilphase comprising at least one penetration enhancing agent, and anon-polymeric thickening agent; and c) an aqueous phase; wherein thesaid composition provides a similar or improved therapeutic effect ascompared to that of the topical composition comprising highest approvedtopical dose of clobetasol i.e. TEMOVATE® and the said compositionprovides mean clobetasol propionate plasma concentrations less thanabout 130 pg/mL. In another embodiment TEMOVATE® is TEMOVATE® cream.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) of clobetasol; b) an oil phasecomprising at least one penetration enhancing agent, and a non-polymericthickening agent; and c) an aqueous phase; wherein the said compositionprovides a similar or improved therapeutic effect as compared to that ofthe topical composition comprising highest approved topical dose ofclobetasol i.e. TEMOVATE® and the said composition provides posttreatment mean clobetasol plasma levels less than about 150 pg/mL. Inanother embodiment TEMOVATE® is TEMOVATE® cream.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) of clobetasol propionate; b) an oilphase comprising at least one penetration enhancing agent, and anon-polymeric thickening agent; and c) an aqueous phase; wherein thesaid composition provides a similar or improved therapeutic effect ascompared to that of the topical composition comprising highest approvedtopical dose of clobetasol i.e. TEMOVATE® and the said compositionprovides post treatment mean clobetasol propionate plasma levels lessthan about 150 pg/mL. In another embodiment TEMOVATE® is TEMOVATE®cream.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) of clobetasol propionate; b) an oilphase comprising at least one penetration enhancing agent, and anon-polymeric thickening agent; and c) an aqueous phase; wherein thesaid composition provides a similar or improved therapeutic effect ascompared to that of the topical composition comprising highest approvedtopical dose of clobetasol i.e. TEMOVATE® and the said compositionprovides post treatment mean clobetasol propionate plasma levels fromabout 130 pg/mL to about 10 pg/ml. In another embodiment TEMOVATE® isTEMOVATE® cream.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) of clobetasol propionate; b) anoil-in-water emulsion comprising a dispersed oil phase comprising atleast one penetration enhancing agent, and a non-polymeric thickeningagent, and a continuous aqueous phase; and c) one or morepharmaceutically acceptable excipients; wherein the said compositionprovides a similar or improved therapeutic effect as compared to thetopical composition comprising highest approved topical dose ofclobetasol i.e. TEMOVATE®.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) of clobetasol propionate; b) anoil-in-water emulsion comprising a dispersed oil phase comprising atleast one penetration enhancing agent, and a non-polymeric thickeningagent, and a continuous aqueous phase; and c) one or morepharmaceutically acceptable excipients; wherein the said compositionprovides a similar or improved therapeutic effect as compared to thetopical composition comprising highest approved topical dose ofclobetasol i.e. TEMOVATE® and the said composition provides meanclobetasol propionate plasma levels less than about 130 pg/mL. Inanother embodiment TEMOVATE® is TEMOVATE® cream.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) of clobetasol propionate; b) anoil-in-water emulsion comprising a dispersed oil phase comprising atleast one penetration enhancing agent, and a non-polymeric thickeningagent, and a continuous aqueous phase; and c) one or morepharmaceutically acceptable excipients; wherein the said compositionprovides a similar or improved therapeutic effect as compared to thetopical composition comprising highest approved topical dose ofclobetasol and the said composition provides post treatment meanclobetasol propionate plasma levels less than about 150 pg/mL. Inanother embodiment TEMOVATE® is TEMOVATE® cream.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) of clobetasol propionate; b) anoil-in-water emulsion comprising a dispersed oil phase comprising atleast one penetration enhancing agent, and a non-polymeric thickeningagent, and a continuous aqueous phase; and c) one or morepharmaceutically acceptable excipients; wherein the said compositionprovides a similar or improved therapeutic effect as compared to thetopical composition comprising highest approved topical dose ofclobetasol i.e. TEMOVATE® and the said composition provides posttreatment mean clobetasol propionate plasma levels from about 130 pg/mLto about 10 pg/ml. In another embodiment TEMOVATE® is TEMOVATE® cream.

In some embodiments, the adverse effect of clobetasol is adverse effectof endocrine system. In some embodiments, the adverse effect ofendocrine system is HPA axis suppression.

In some embodiments, the adverse effect of clobetasol is reduction inserum concentration of dehydroepiandrosterone (DHEA) and/ordehydroepiandrosterone sulfate (DHEAS).

In some embodiments of the present invention TEMOVATE® is TEMOVATE®cream.

In some embodiments, the topical compositions of the present inventioncomprises 0.025% (w/w) clobetasol, provides lower percentage reductionof serum concentration of DHEAS. The percentage reduction of DHEAS serumconcentration is less than about 18% or is less than about 15% or isless than about 10% or is less than about 5%. In some embodiments,0.025% (w/w) clobetasol of the present invention provides the percentagereduction of DHEAS serum concentration is about 18% or 17% or 16% or 15%or 14% or 13% or 12% or 11% or 10% or 9% or 8% or 7% or 6% or 5% or 4%or 3% or 2% or 1%, wherein the percentage reduction of serumconcentration of DHEAS is lower than that of TEMOVATE®.

In some embodiments, the topical compositions of the present inventioncomprises 0.025% (w/w) clobetasol, provides the percentage reduction ofDHEAS serum concentration is at least about 20% or is at least about 30%or is at least about 40% or is at least about 55%, when compared to thatof TEMOVATE®.

In some embodiments, the topical compositions of the present inventioncomprises 0.025% (w/w) clobetasol propionate, provides lower percentagereduction of serum concentration of DHEAS. The percentage reduction ofDHEAS serum concentration is less than about 18% or is less than about15% or is less than about 10% or is less than about 5%. In someembodiments, 0.025% (w/w) clobetasol propionate of the present inventionprovides the percentage reduction of DHEAS serum concentration is about18% or 17% or 16% or 15% or 14% or 13% or 12% or 11% or 10% or 9%6 or 8%or 7% or 6° % or 5% or 4% or 3% or 2% or 1%, wherein the percentagereduction of serum concentration of DHEAS is lower than that ofTEMOVATE®.

In some embodiments, the topical compositions of the present inventioncomprises 0.025% (w/w) clobetasol propionate, provides the percentagereduction of DHEAS serum concentration is at least about 20% or is atleast about 30% or is at least about 40% or is at least about 55% whencompared to that of TEMOVATE® cream.

In some embodiments, the topical compositions of the present inventioncomprises from about 0.005% (w/w) to about 0.04% (w/w) clobetasol,provides the percentage reduction of DHEAS serum concentration is about18% or 17% or 16% or 15% or 14% or 13% or 12% or 11% or 10% or 9% or 8%or 7% or 6% or 5% or 4% or 3% or 2% or 1%, wherein the percentagereduction of serum concentration of DHEAS is lower than that ofTEMOVATE®.

In some embodiments, the topical compositions of the present inventioncomprises about 0.025% (w/w) clobetasol, provides lower percentage ofreduction of DHEAS serum concentration as compared to that of TEMOVATE®.

In some embodiments, the topical composition of the present inventioncomprises 25% (w/w) clobetasol provides therapeutically beneficialeffects of clobetasol which is substantially free of adverse effect ofclobetasol wherein the said adverse effect is HPA axis suppressionand/or reduction in serum concentration of dehydroepiandrosterone (DHEA)and/or dehydroepiandrosterone sulfate (DHEAS).

In some embodiments, the topical composition of the present inventioncomprises a low-dose clobetasol, wherein the said composition providessubstantially free of HPA axis suppression in a subject.

In some embodiments, the topical composition of the present inventioncomprises about 0.025% (w/w) clobetasol, wherein the said compositionprovides substantially free of HPA axis suppression in a subject.

In some embodiments, the topical composition of the present inventioncomprises about 0.025% (w/w) clobetasol, wherein the said compositionprovides substantially free of HPA axis suppression, when compared tothat of TEMOVATE®.

In some embodiments, the topical composition of the present inventioncomprises about 0.025% (w/w) clobetasol propionate, wherein the saidcomposition provides substantially free of HPA axis suppression in asubject.

In some embodiments, the topical composition of the present inventioncomprises about 0.025% (w/w) clobetasol propionate, wherein the saidcomposition provides substantially free of HPA axis suppression, whencompared to that of TEMOVATE®.

In some embodiments, the topical composition of the present inventioncomprises about 0.025% (w/w) clobetasol propionate, wherein the saidcomposition provides post treatment mean plasma concentration ofclobetasol propionate less than about 150 pg/ml, and providessubstantially free of HPA axis suppression, when compared to that ofTEMOVATE®.

In some embodiments, the topical composition of the present inventioncomprises a low-dose clobetasol, wherein the said composition provideslower percentage reduction of serum concentration of DHEAS, whencompared to that of TEMOVATE®.

In some embodiments, the topical composition of the present inventioncomprises 0.025% (w/w) clobetasol, wherein the said composition provideslower percentage reduction of serum concentration of DHEAS, whencompared to that of TEMOVATE®. In some embodiments, the percentagereduction is less than about 15%.

In some embodiments, the topical composition of the present inventioncomprises 0.025% (w/w) clobetasol propionate, wherein the saidcomposition provides lower percentage reduction of serum concentrationof DHEAS, when compared to that of TEMOVATE®. In some embodiments, thepercentage reduction is less than about 15%

In some embodiments, the topical composition of the present inventioncomprises about 0.025% (w/w) clobetasol, wherein the said compositionprovides lower percentage of reduction of serum concentration of DHEAS,when compared to that of TEMOVATE®. In some embodiments, the topicalcomposition of the present invention comprises about 0.025% (w/w)clobetasol propionate, wherein the said composition provides posttreatment mean plasma concentration of clobetasol propionate less thanabout 150 pg/ml, and provides lower percentage of reduction of serumconcentration of DHEAS, when compared to that of TEMOVATE®.

In some embodiments, the topical composition of the present inventioncomprises about 0.025% (w/w) clobetasol, wherein the said compositionprovides post treatment mean plasma concentration of clobetasol lessthan about 150 pg/ml, and provides lower percentage of reduction ofserum concentration of DHEAS and further provides substantially free ofHPA axis suppression, when compared to that of TEMOVATE®

In some embodiments, the topical composition of the present inventioncomprises about 0.025% (w/w) clobetasol propionate, wherein the saidcomposition provides post treatment mean plasma concentration ofclobetasol propionate less than about 150 pg/ml, and provides lowerpercentage of reduction of serum concentration of DHEAS and furtherprovides substantially free of HPA axis suppression, when compared tothat of TEMOVATE®

In some embodiments, the percentage reduction in DHEA or DHEAS serumlevels is a parameter for adverse effect of steroid drug such asclobetasol. The topical compositions of the present invention provideslower percentage reduction in serum concentration of DHEA or DHEAS.

In some embodiments, the topical composition of the present inventioncomprises a) a low-dose clobetasol; b) an oil phase comprising at leastone penetration enhancing agent, and a non-polymeric thickening agent;and c) an aqueous phase; which provides a similar or improvedtherapeutic effect of highest approved topical dose of clobetasol i.e.TEMOVATE® and provides substantially free of adverse effect, wherein theadverse effect is effect on endocrine system such as adrenal gland whichin turn causes HPA axis suppression.

In some embodiments, the topical composition of the present inventioncomprises a) a low-dose clobetasol; b) an oil phase comprising at leastone penetration enhancing agent, and a non-polymeric thickening agent;and c) an aqueous phase; which provides a similar or improvedtherapeutic effect of highest approved topical dose of clobetasol i.e.TEMOVATE® and provides substantially free of adverse effect, wherein theadverse effect is reduced levels of dehydroepiandrosterone sulfate(DHEAS).

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol; b) an oil phase comprisingat least one penetration enhancing agent, and a non-polymeric thickeningagent; and c) an aqueous phase; which provides a similar or improvedtherapeutic effect of highest approved topical dose of clobetasol i.e.TEMOVATE® and provides substantially free of adverse effect, wherein theadverse effect is effect on endocrine system such as adrenal gland whichin turn causes HPA axis suppression.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol; b) an oil phase comprisingat least one penetration enhancing agent, and a non-polymeric thickeningagent; and c) an aqueous phase; which provides a similar or improvedtherapeutic effect of highest approved topical dose of clobetasol i.e.TEMOVATE® and provides substantially free of adverse effect, wherein theadverse effect is reduced levels of dehydroepiandrosterone sulfate(DHEAS).

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol propionate; b) an oil phasecomprising at least one penetration enhancing agent, and a non-polymericthickening agent; and c) an aqueous phase; which provides a similar orimproved therapeutic effect of highest approved topical dose ofclobetasol i.e. TEMOVATE® and provides substantially free of adverseeffect, wherein the adverse effect is effect on endocrine system such asadrenal gland which in turn causes HPA axis suppression.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol propionate; b) an oil phasecomprising at least one penetration enhancing agent, and a non-polymericthickening agent; and c) an aqueous phase; which provides a similar orimproved therapeutic effect of highest approved topical dose ofclobetasol i.e. TEMOVATE® and provides substantially free of adverseeffect, wherein the said adverse effect is reduced levels ofdehydroepiandrosterone sulfate (DHEAS).

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol propionate; b) an oil phasecomprising at least one penetration enhancing agent, and a non-polymericthickening agent; and c) an aqueous phase; which provides a similar orimproved therapeutic effect of highest approved topical dose ofclobetasol i.e. TEMOVATE® and provides substantially free of adverseeffects, wherein the adverse effects are HPA axis suppression andreduced levels of dehydroepiandrosterone sulfate (DHEAS).

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol propionate; b) an oil phasecomprises at least one penetration enhancing agent, and a non-polymericthickening agent; and c) an aqueous phase; which provides a similar orimproved therapeutic effect of highest approved topical dose ofclobetasol i.e. TEMOVATE® and provides substantially free of adverseeffects, wherein the adverse effects are HPA axis suppression andreduced levels of dehydroepiandrosterone sulfate (DHEAS).

In some embodiments, the topical composition of the present inventioncomprises a) a low-dose clobetasol; b) an oil phase comprising at leastone penetration enhancing agent, and a non-polymeric thickening agent;and c) an aqueous phase; which provides a similar or improvedtherapeutic effect of highest approved topical dose of clobetasol i.e.TEMOVATE® and provides mean clobetasol plasma levels insufficient toreduce serum levels of cortisol less than or equal to about 18 ug/dL.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol; b) an oil phase comprisingat least one penetration enhancing agent, and a non-polymeric thickeningagent; and c) an aqueous phase; which provides a similar or improvedtherapeutic effect of highest approved topical dose of clobetasol i.e.TEMOVATE® and provides mean clobetasol plasma levels insufficient toreduce serum levels of cortisol less than or equal to about 18 ug/dL.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol propionate; b) an oil phasecomprising at least one penetration enhancing agent, and a non-polymericthickening agent; and c) an aqueous phase; which provides a similar orimproved therapeutic effect of highest approved topical dose ofclobetasol i.e. TEMOVATE® and provides mean clobetasol propionate plasmalevels insufficient to reduce serum levels of cortisol less than orequal to about 18 ug/dL.

In some embodiments, the topical composition of present inventioncomprises about 0.025% (w/w) clobetasol, wherein the said compositionprovides the post treatment mean clobetasol plasma concentration issignificantly lower than that of TEMOVATE®, and the mean plasmaconcentrations are measured post 2 weeks treatment period.

In some embodiments, the topical composition of present inventioncomprises about 0.025% (w/w) clobetasol propionate, wherein the saidcomposition provides the post treatment mean clobetasol propionateplasma concentration is significantly lower than that of TEMOVATE®, andthe mean plasma concentrations are measured post two weeks treatmentperiod.

In some embodiments, post treatment plasm concentrations are measuredpost 8 weeks treatment period.

In some embodiments, post treatment plasm concentrations are measuredpost 4 weeks treatment period.

In some embodiments, post treatment plasm concentrations are measuredpost 15 days treatment period.

In some embodiments, the topical composition of present inventioncomprises about 0.025% (w/w) of clobetasol propionate, wherein the saidcomposition provides the post treatment mean plasma concentration issignificantly lower than that of TEMOVATE®. The mean plasmaconcentrations are measured post 15 days or two weeks treatment. In someembodiments, the post treatment mean clobetasol propionate plasma levelsare less than about 150 pg/ml. In some aspects, the post treatment meanclobetasol propionate plasma levels are less than about 130 pg/ml, orthe post treatment mean clobetasol propionate plasma levels are lessthan about 100 pg/ml or the post treatment mean clobetasol propionateplasma levels are less than about 75 pg/ml or the post treatment meanclobetasol propionate plasma levels are less than about 50 pg/ml or thepost treatment mean clobetasol propionate plasma levels are less thanabout 25 pg/ml or the post treatment mean clobetasol propionate plasmalevels are below quantifiable level. In some embodiments, the topicalcomposition of present invention comprises from about 0.005% (w/w) toabout 0.04% (w/w) of clobetasol, wherein the said composition providesthe post treatment mean plasma concentration is significantly lower thanthat of TEMOVATE®, and the mean plasma concentrations are measured posteight weeks treatment or post four weeks treatment or post two weekstreatment.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol; b) an oil phase comprisingat least one penetration enhancing agent, and a non-polymeric thickeningagent; and c) an aqueous phase; which provides a similar or improvedtherapeutic effect of highest approved topical dose of clobetasol i.e.TEMOVATE® and provides mean clobetasol plasma levels in the range offrom about 130 pg/mL to 0 pg/mL.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol; b) an oil-in-water emulsioncomprising a dispersed oil phase comprising at least one penetrationenhancing agent, and a non-polymeric thickening agent, and a continuousaqueous phase; and c) one or more pharmaceutically acceptableexcipients; which provides a similar or improved therapeutic effect ofhighest approved topical dose of clobetasol i.e. TEMOVATE® and providesmean clobetasol plasma levels in the range of from about 130 pg/mL to 0pg/mL.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol propionate; b) an oil phasecomprising at least one penetration enhancing agent, and a non-polymericthickening agent; and c) an aqueous phase; which provides a similar orimproved therapeutic effect of highest approved topical dose ofclobetasol i.e. TEMOVATE® and provides mean clobetasol propionate plasmalevels in the range of from about 130 pg/mL to 0 pg/mL.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol propionate; b) anoil-in-water emulsion comprising a dispersed oil phase comprising atleast one penetration enhancing agent, and a non-polymeric thickeningagent, and a continuous aqueous phase; and c) one or morepharmaceutically acceptable excipients; which provides a similar orimproved therapeutic effect of highest approved topical dose ofclobetasol i.e. TEMOVATE® and provides mean clobetasol propionate plasmalevels in the range of from about 130 pg/mL to 0 pg/mL. In someembodiments, clobetasol propionate plasma levels are in the range offrom about 120 pg/mL to about 20 pg/mL or in the range of 100 pg/mL to20 pg/mL or

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol propionate; b) anoil-in-water emulsion comprising a dispersed oil phase comprising atleast one penetration enhancing agent, and a non-polymeric thickeningagent, and a continuous aqueous phase; and c) one or morepharmaceutically acceptable excipients; which provides a similar orimproved therapeutic effect of TEMOVATE® and provides post treatmentmean clobetasol propionate plasma levels in the range of from about 150pg/mL to 0 pg/mL. In some embodiments, clobetasol propionate plasmalevels are in the range of about 130 pg/mL to 0 pg/mL or about 100 pg/mLto about 10 pg/mL.

In some embodiments, the composition of the present invention providesmean plasma concentration which is insufficient to cause clinicallysignificant HPA axis suppression.

In some embodiments, the composition of the present invention providesmean plasma concentration which provides lower percentage reduction inserum levels of DHEAS

In some embodiments, the composition of the present invention providesmean plasma concentrations which causes substantially free of HPA axissuppression and provides lower percentage reduction in serum levels ofDHEAS.

In some embodiments, the topical composition of the present inventioncomprises a low-dose clobetasol provides post treatment mean clobetasolplasma concentration, which causes substantially free of HPA axissuppression. and/or lower percentage reduction in serum levels of DHEAS.

In some embodiments, the topical composition of the present inventioncomprises about 0.025% (w/w) clobetasol provides post treatment meanclobetasol plasma concentration, which causes substantially free of HPAaxis suppression; and/or lower percentage reduction in serum levels ofDHEAS.

In some embodiments, the topical composition of the present inventioncomprises about 0.025% (w/w) clobetasol propionate provides posttreatment mean clobetasol plasma concentration, which causessubstantially free of HPA axis suppression; and/or lower percentagereduction in serum levels of DHEAS.

In some embodiments, the topical composition of the present inventioncomprises about 0.025% (w/w) clobetasol propionate provides posttreatment mean clobetasol propionate plasma concentration, which causessubstantially free of HPA axis suppression; or lower percentagereduction in serum levels of DHEAS.

In some embodiments, the topical composition of present inventioncomprises about 0.025% (w/w) clobetasol propionate provides meanclobetasol propionate plasma levels less than or equal to about 130pg/ml or 129 or 128 or 127 or 126 or 125 or 124 or 123 or 122 or 121 or120 or 119 or 118 or 117 or 116 or 115 or 114 or 113 or 112 or 111 or110 or 109 or 108 or 107 or 106 or 105 or 104 or 103 or 102 or 101 or100 or 99 or 98 or 97 or 96 or 95 or 94 or 93 or 92 or 91 or 90 or 89 or88 or 87 or 86 or 85 or 84 or 83 or 82 or 81 or 80 or 79 or 78 or 77 or76 or 75 or 74 or 73 or 72 or 71 or 70 or 69 or 68 or 67 or 66 or 65 or64 or 63 or 62 or 61 or 60 or 59 or 58 or 57 or 56 or 55 or 54 or 53 or52 or 51 or 50 or 49 or 48 or 47 or 46 or 45 or 44 or 43 or 42 or 41 or40 or 39 or 38 or 37 or 36 or 35 or 34 or 33 or 32 or 31 or 30 or 29 or28 or 27 or 26 or 25 or 24 or 23 or 22 or 21 or 20 or 19 or 18 or 17 or16 or 15 or 14 or 13 or 12 or 11 or 10 or 9 or 8 or 7 or 6 or 5 or 4 or3 or 2 or 1 or 0 pg/mL in a subject when administered for 15 days andprovides substantially free of HPA axis suppression.

In some embodiments, the topical composition of present inventioncomprises about 0.025% (w/w) clobetasol propionate provides meanclobetasol propionate plasma levels less than or equal to about 130pg/ml or 129 or 128 or 127 or 126 or 125 or 124 or 123 or 122 or 121 or120 or 119 or 118 or 117 or 116 or 115 or 114 or 113 or 112 or 111 or110 or 109 or 108 or 107 or 106 or 105 or 104 or 103 or 102 or 101 or100 or 99 or 98 or 97 or 96 or 95 or 94 or 93 or 92 or 91 or 90 or 89 or88 or 87 or 86 or 85 or 84 or 83 or 82 or 81 or 80 or 79 or 78 or 77 or76 or 75 or 74 or 73 or 72 or 71 or 70 or 69 or 68 or 67 or 66 or 65 or64 or 63 or 62 or 61 or 60 or 59 or 58 or 57 or 56 or 55 or 54 or 53 or52 or 51 or 50 or 49 or 48 or 47 or 46 or 45 or 44 or 43 or 42 or 41 or40 or 39 or 38 or 37 or 36 or 35 or 34 or 33 or 32 or 31 or 30 or 29 or28 or 27 or 26 or 25 or 24 or 23 or 22 or 21 or 20 or 19 or 18 or 17 or16 or 15 or 14 or 13 or 12 or 11 or 10 or 9 or 8 or 7 or 6 or 5 or 4 or3 or 2 or 1 or 0 pg/mL in a subject when administered for 15 days andprovides lower percentage reduction in DHEAS serum concentration.

In some embodiments, the topical composition of present inventioncomprises about 0.025% (w/w) clobetasol propionate provides posttreatment mean clobetasol propionate plasma concentration less than orequal to about 150 pg/ml or 149 or 148 or 147 or 146 or 145 or 144 or143 or 142 or 141 or 140 or 139 or 138 or 137 or 136 or 135 or 134 or133 or 132 or 131 or 131 or 129 or 128 or 127 or 126 or 125 or 124 or123 or 122 or 121 or 120 or 119 or 118 or 117 or 116 or 115 or 114 or113 or 112 or 111 or 110 or 109 or 108 or 107 or 106 or 105 or 104 or103 or 102 or 101 or 100 or 99 or 98 or 97 or 96 or 95 or 94 or 93 or 92or 91 or 90 or 89 or 88 or 87 or 86 or 85 or 84 or 83 or 82 or 81 or 80or 79 or 78 or 77 or 76 or 75 or 74 or 73 or 72 or 71 or 70 or 69 or 68or 67 or 66 or 65 or 64 or 63 or 62 or 61 or 60 or 59 or 58 or 57 or 56or 55 or 54 or 53 or 52 or 51 or 50 or 49 or 48 or 47 or 46 or 45 or 44or 43 or 42 or 41 or 40 or 39 or 38 or 37 or 36 or 35 or 34 or 33 or 32or 31 or 30 or 29 or 28 or 27 or 26 or 25 or 24 or 23 or 22 or 21 or 20or 19 or 18 or 17 or 16 or 15 or 14 or 13 or 12 or 11 or 10 or 9 or 8 or7 or 6 or 5 or 4 or 3 or 2 or 1 or 0 pg/mL in a subject whenadministered for 15 days, and provides substantially free of HPA axissuppression.

In some embodiments, the topical composition of present inventioncomprises about 0.025% (w/w) clobetasol propionate provides posttreatment mean clobetasol propionate plasma concentration less than orequal to about 150 pg/ml or 149 or 148 or 147 or 146 or 145 or 144 or143 or 142 or 141 or 140 or 139 or 138 or 137 or 136 or 135 or 134 or133 or 132 or 131 or 131 or 129 or 128 or 127 or 126 or 125 or 124 or123 or 122 or 121 or 120 or 119 or 118 or 117 or 116 or 115 or 114 or113 or 112 or 111 or 110 or 109 or 108 or 107 or 106 or 105 or 104 or103 or 102 or 101 or 100 or 99 or 98 or 97 or 96 or 95 or 94 or 93 or 92or 91 or 90 or 89 or 88 or 87 or 86 or 85 or 84 or 83 or 82 or 81 or 80or 79 or 78 or 77 or 76 or 75 or 74 or 73 or 72 or 71 or 70 or 69 or 68or 67 or 66 or 65 or 64 or 63 or 62 or 61 or 60 or 59 or 58 or 57 or 56or 55 or 54 or 53 or 52 or 51 or 50 or 49 or 48 or 47 or 46 or 45 or 44or 43 or 42 or 41 or 40 or 39 or 38 or 37 or 36 or 35 or 34 or 33 or 32or 31 or 30 or 29 or 28 or 27 or 26 or 25 or 24 or 23 or 22 or 21 or 20or 19 or 18 or 17 or 16 or 15 or 14 or 13 or 12 or 11 or 10 or 9 or 8 or7 or 6 or 5 or 4 or 3 or 2 or 1 or 0 pg/mL in a subject whenadministered for 15 days, and provides lower percentage reduction inDHEAS serum concentration.

In some embodiments, the topical composition of the present inventioncomprises a) about 0.025% (w/w) clobetasol propionate; b) an oil phasecomprising at least one penetration enhancing agent, and a non-polymericthickening agent; and c) an aqueous phase; which provides a similar orimproved therapeutic effect of highest approved topical dose ofclobetasol i.e. TEMOVATE® and provides median clobetasol propionateplasma levels insufficient to reduce serum levels of cortisol less thanor equal to about 18 ug/dL.

In some embodiments, the present invention relates to a method forprophylaxis, amelioration, or treatment of psoriasis, relief of theinflammatory and pruritic manifestations of steroid responsivedermatoses, erythema, contact sensitivity reactions, and otherassociated diseases or disorders, by administering to a subject,comprising administration a low-dose clobetasol, to the affected area ofthe skin once or twice daily at least for one day; wherein the saidcomposition provides a similar or improved therapeutic effect of highestapproved topical dose of clobetasol i.e. TEMOVATE® and providessubstantially free of HPA axis suppression. In some embodiments,low-dose clobetasol is about 0.025% (w/w) clobetasol. In someembodiments, low-dose clobetasol is about 0.025% (w/w) clobetasolpropionate.

In some embodiments, the present invention relates to a method forprophylaxis, amelioration, or treatment of psoriasis, relief of theinflammatory and pruritic manifestations of steroid responsivedermatoses, erythema, contact sensitivity reactions, and otherassociated diseases or disorders, by administering to a subject,comprising administration a low-dose clobetasol, to the affected area ofthe skin once or twice daily up to about two weeks; wherein the saidcomposition provides a similar or improved therapeutic effect of highestapproved topical dose of clobetasol i.e. TEMOVATE® and providessubstantially free of HPA axis suppression. In some embodiments,low-dose clobetasol is about 0.025% (w/w) clobetasol. In someembodiments, low-dose clobetasol is about 0.025% (w/w) clobetasolpropionate.

In some embodiments, the present invention relates to a method forprophylaxis, amelioration, or treatment of psoriasis, relief of theinflammatory and pruritic manifestations of steroid responsivedermatoses, erythema, contact sensitivity reactions, and otherassociated diseases or disorders, by administering to a subject,comprising administration a low-dose clobetasol, to the affected area ofthe skin once or twice daily up to about four weeks; wherein the saidcomposition provides a similar or improved therapeutic effect of highestapproved topical dose of clobetasol i.e. TEMOVATE® and providessubstantially free of HPA axis suppression. In some embodiments,low-dose clobetasol is about 0.025% (w/w) clobetasol. In someembodiments, low-dose clobetasol is about 0.025% (w/w) clobetasolpropionate.

In some embodiments, the present invention relates to a method forprophylaxis, amelioration, or treatment of psoriasis, relief of theinflammatory and pruritic manifestations of steroid responsivedermatoses, erythema, contact sensitivity reactions, and otherassociated diseases or disorders, by administering to a subject,comprising administration a low-dose clobetasol, to the affected area ofthe skin once or twice daily at least for one day; wherein the saidcomposition provides a similar or improved therapeutic effect of highestapproved topical dose of clobetasol i.e. TEMOVATE® and provides lowerpercentage of reduction in DHEAS. In some embodiments, low-doseclobetasol is about 0.025% (w/w) clobetasol. In some embodiments,low-dose clobetasol is about 0.025% (w/w) clobetasol propionate.

In some embodiments, the present invention relates to a method forprophylaxis, amelioration, or treatment of psoriasis, relief of theinflammatory and pruritic manifestations of steroid responsivedermatoses, erythema, contact sensitivity reactions, and otherassociated diseases or disorders, by administering to a subject,comprising administration a low-dose clobetasol, to the affected area ofthe skin once or twice daily up to about two weeks; wherein the saidcomposition provides a similar or improved therapeutic effect of highestapproved topical dose of clobetasol i.e. TEMOVATE® and provides lowerpercentage of reduction in DHEAS. In some embodiments, low-doseclobetasol is about 0.025% (w/w) clobetasol. In some embodiments,low-dose clobetasol is about 0.025% (w/w) clobetasol propionate.

In some embodiments, the present invention relates to a method forprophylaxis, amelioration, or treatment of psoriasis, relief of theinflammatory and pruritic manifestations of steroid responsivedermatoses, erythema, contact sensitivity reactions, and otherassociated diseases or disorders, by administering to a subject,comprising administration a low-dose clobetasol, to the affected area ofthe skin once or twice daily up to about four weeks; wherein the saidcomposition provides a similar or improved therapeutic effect of highestapproved topical dose of clobetasol i.e. TEMOVATE® and provides lowerpercentage of reduction in DHEAS. In some embodiments, low-doseclobetasol is about 0.025% (w/w) clobetasol. In some embodiments,low-dose clobetasol is about 0.025% (w/w) clobetasol propionate.

In some embodiments, the method of treating psoriasis in a subject, thesaid method comprises topical administration of a composition comprisinga low-dose of clobetasol, to the subject to affected areas of the skinonce or twice daily for at least one day to about two weeks; wherein thesaid composition is substantially free of adverse effects and provides asimilar or improved therapeutic effect as compared to that of thetopical composition comprising highest approved topical dose ofclobetasol i.e. TEMOVATE®. In some embodiments, low-dose clobetasol isabout 0.025% (w/w) clobetasol. In some embodiments, low-dose clobetasolis about 0.025% (w/w) clobetasol propionate.

In some embodiments, the present invention relates to a method oftreating psoriasis in a subject, the said method comprises a topicaladministration of a composition, comprising about 0.025% (w/w) ofclobetasol, to the subject's affected areas of the skin; wherein thesaid composition is substantially free of adverse effects and provides asimilar or improved therapeutic effect as compared to that of thetopical composition comprising highest approved topical dose ofclobetasol i.e. TEMOVATE®.

In some embodiments, the method of treating psoriasis involves topicaladministration of a composition comprising from about 0.005% to about0.04% (w/w) of clobetasol, to the subject, once daily to the affectedareas of the skin twice daily for a period of from about one day to twoweeks to the affected areas of the skin for a period of from about oneday to two weeks, or once daily to the affected areas of the skin for aperiod of from about one day to about four weeks or twice daily to theaffected areas of the skin for a period of from about one day to aboutfour weeks.

In some embodiments, the method of treating psoriasis involves topicaladministration of a composition comprising about 0.025% (w/w)clobetasol, to the subject, once daily to the affected areas of the skintwice daily for a period of about two weeks to the affected areas of theskin for a period of about two weeks, or once daily to the affectedareas of the skin for a period of about four weeks or twice daily to theaffected areas of the skin for a period of about four weeks. In someembodiments, the composition comprises about 0.025% (w/w) clobetasolpropionate.

In some embodiments, the method of treating psoriasis involves topicaladministration of a composition comprising about 0.025% (w/w) ofclobetasol to the subject, wherein the said subject having psoriaticlesions involving at least about 5% body surface area or from about 5%to about 10% body surface area or more than about 10% body surface area.In some embodiments, the composition is comprises about 0.025% (w/w)clobetasol propionate.

In some embodiments, the composition of the present invention isadministered once or twice daily.

In some embodiments, the method of treating psoriasis in a subject, thesaid method comprises a topical administration of a compositioncomprising about 0.025% (w/w) of clobetasol propionate, to the subjectonce or twice daily to affected areas of the skin for about two weeks toabout four weeks; wherein the said composition is substantially free ofadverse effects and provides a similar or improved therapeutic effect ascompared to that of the topical composition comprising highest approvedtopical dose of clobetasol i.e. TEMOVATE® and the said compositionprovides mean clobetasol propionate plasma levels less than about 130pg/mL.

In some embodiments, the method of treating psoriasis in a subjects, thesaid method comprises a topical administration of a compositioncomprising about 0.025% (w/w) of clobetasol propionate, to the subjectonce or twice daily to affected areas of the skin for about two weeks toabout four weeks; wherein the said composition is substantially free ofadverse effects and provides a similar or improved therapeutic effect ascompared to that of the topical composition comprising highest approvedtopical dose of clobetasol i.e. TEMOVATE® and the said compositionprovides post treatment mean clobetasol propionate plasma levels lessthan about 150 pg/mL.

In some embodiments, the method of treating psoriasis in a subject, thesaid method comprises a topical administration of a compositioncomprising about 0.025% (w/w) of clobetasol propionate, to the subjectonce or twice daily to affected areas of the skin for about two weeks toabout four weeks; wherein the said composition is substantially free ofadverse effects and provides a similar or improved therapeutic effect ascompared to that of TEMOVATE® and the said composition provides posttreatment mean clobetasol propionate plasma levels less than about 150pg/mL.

In some embodiments, the method of treating psoriasis in a subject, thesaid method comprises a topical administration of a compositioncomprising about 0.025% (w/w) of clobetasol propionate, to the subjectonce or twice daily to affected areas of the skin for about two week toabout four weeks; wherein the said composition is substantially free ofadverse effects and provides a similar or improved therapeutic effect ascompared to that of TEMOVATE® and the said composition provides posttreatment mean clobetasol propionate plasma levels about from 130 pg/mLto 0 pg/ml.

In some embodiments, the method of treating psoriasis in a subject, thesaid method comprises a topical administration of a compositioncomprising about 0.025% (w/w) of clobetasol propionate, to the subjectonce or twice daily to affected areas of the skin for a period of fromabout two weeks to about four weeks; wherein the said composition issubstantially free of adverse effects and provides a similar or improvedtherapeutic effect as compared to that of TEMOVATE® and the saidcomposition provides post treatment mean clobetasol propionate plasmalevels about from 150 pg/mL to 0 pg/ml.

In some embodiments, the method of treating psoriasis in a subjects, thesaid method comprises: topical administration of a compositioncomprising about 0.025% (w/w) of clobetasol propionate, to the subjectonce or twice daily to affected areas of the skin for a period of abouttwo weeks; wherein the said composition is substantially free of adverseeffects and provides a similar or improved therapeutic effect ascompared to that of TEMOVATE® and the said composition provides posttreatment mean clobetasol propionate plasma levels about from 150 pg/mLto 0 pg/ml.

In some embodiments, the present invention relates to a method oftreating psoriasis in a subject having psoriatic lesions more than about10% body surface area, the said method comprising topical administrationof a composition, comprising about 0.025% (w/w) of clobetasolpropionate, to the subject's affected areas of the skin twice daily fora treatment period of about four weeks; wherein the said method providessubstantially free of adverse effects and provides a similar or improvedtherapeutic effect as compared to that of the topical compositioncomprising highest approved topical dose of clobetasol i.e. TEMOVATE®.In some embodiments, the topical administration of a compositioncomprising about 0.025% (w/w) clobetasol propionate, involves once ortwice daily for a treatment period of four weeks. In some embodiments,the adverse effects are HPA axis suppression and/or reduction in DHEAS.

In some embodiments, the present invention provides a method of treatingpsoriasis in a subject, wherein the topical composition, comprising alow-dose clobetasol, is administered topically to the subject's affectedskin area and said treatment provides a similar or an improvedtherapeutic effect and is substantially free of adverse effects ascompared to that of TEMOVATE®. In some embodiments the composition iscomprising about 0.025% (w/w) clobetasol. In some embodiments, thecomposition is comprising about 0.025% (w/w) clobetasol propionate.

In some embodiments, the present invention provides a method of treatingpsoriasis in a subject, wherein said topical composition, comprisingabout 0.025% of clobetasol, is administered topically to the subject'saffected skin area and said treatment provides lower percentage ofreduction in serum concentration of dehydroepiandrosterone sulfate(DHEAS) and has a similar or improved therapeutic effect as compared tothat of TEMOVATE®. In some embodiments, the composition is comprisesabout 0.025% (w/w) clobetasol propionate.

In some embodiments, the present invention provides a method of treatingpsoriasis in a subject, wherein said topical composition, comprisingabout 0.025% (w/w) of clobetasol, is administered topically to thesubject's affected skin area and said treatment provides lowerpercentage of reduction in serum concentration of dehydroepiandrosteronesulfate (DHEAS) and substantially free of HPA axis suppression; and hasa similar or improved therapeutic effect as compared to that ofTEMOVATE®. In some embodiments, the composition is comprises about0.025% (w/w) clobetasol propionate.

In some embodiments, the present invention provides a method of treatinga subject having psoriatic lesions more than about 10% of the bodysurface area, wherein the topical composition comprising low-doseclobetasol is administered to said subject's surface area and suchtreatment provides substantially no hypothalamic pituitary adrenal (HPA)axis suppression, lower percentage of reduction in serum concentrationof dehydroepiandrosterone sulfate (DHEAS) with a similar or improvedtherapeutic effect as compared to that of TEMOVATE®. In some embodimentsthe composition is comprising about 0.025% (w/w) clobetasol. In someembodiments, the composition is comprising about 0.025% (w/w) clobetasolpropionate.

In some embodiments, the present invention provides a method of treatingpsoriasis in a subject, wherein the topical composition, comprisinglow-dose clobetasol, is administered topically to the subject's affectedskin area and said treatment provides a lower percentage of reduction inserum concentration of dehydroepiandrosterone sulfate (DHEAS) and lowpost treatment clobetasol mean plasma concentration in the subjects withno HPA axis suppression as compared to that of subjects with significantHPA axis suppression.

In some embodiments, the present invention provides a method of treatingpsoriasis in a subject, wherein the topical composition, comprisingabout 0.025% (w/w) clobetasol propionate, is administered topically tothe subject's affected skin area and said treatment provides a lowerpercentage of reduction in serum concentration of dehydroepiandrosteronesulfate (DHEAS) and low post treatment clobetasol propionate mean plasmaconcentration in the subjects with no HPA axis suppression as comparedto that of subjects with significant HPA axis suppression.

In some embodiments, the present invention provides a method of treatingpsoriasis in a subject, wherein the topical composition, comprisinglow-dose clobetasol, is administered topically to the subject's affectedskin area and said treatment provides a lower percentage of reduction inserum concentration of dehydroepiandrosterone sulfate (DHEAS) and lowpost treatment clobetasol mean plasma concentration in the subjects withsignificantly no HPA axis suppression as compared to that of subjectswith significant HPA axis suppression.

In some embodiments, the present invention provides a method of treatingpsoriasis in a subject, wherein the topical composition, comprisingabout 0.025% (w/w) clobetasol, is administered topically to thesubject's affected skin area once or twice daily for a period of atleast one day to about four weeks; and said treatment provides lowerpercentage of reduction in serum concentration of dehydroepiandrosteronesulfate (DHEAS) and low post treatment clobetasol plasma concentrationin the subjects with significantly no HPA axis suppression as comparedto that of subjects with significant HPA axis suppression.

In some embodiments, the present invention provides a method of treatingpsoriasis in a subject, wherein the topical composition, comprisingabout 0.025% (w/w) clobetasol propionate, is administered topically tothe subject's affected skin area for a period of at least one day toabout four weeks; and said treatment provides lower percentage ofreduction in serum concentration of dehydroepiandrosterone sulfate(DHEAS) and low post treatment clobetasol propionate plasmaconcentration in the subjects with significantly no HPA axis suppressionas compared to that of subjects with significant HPA axis suppression.

In some embodiments, the present invention provides a method of treatingpsoriasis in a subject, wherein the topical composition, comprisingabout 0.025% (w/w) clobetasol, is administered topically to thesubject's affected skin area for a period of at least one day to abouttwo weeks; and said treatment provides lower percentage of reduction inserum concentration of dehydroepiandrosterone sulfate (DHEAS) and lowpost treatment clobetasol plasma concentration in the subjects with noHPA axis suppression as compared to that of subjects with significantHPA axis suppression.

In some embodiments, the present invention provides a method of treatingpsoriasis in a subject, wherein the topical composition, comprisingabout 0.025% (w/w) clobetasol propionate, is administered topically tothe subject's affected skin area for a period of at least one day toabout two weeks; and said treatment provides lower percentage ofreduction in serum concentration of dehydroepiandrosterone sulfate(DHEAS) and low post treatment clobetasol propionate plasmaconcentration in the subjects with no HPA axis suppression as comparedto that of subjects with significant HPA axis suppression.

In some embodiments, the present invention provides a method of treatingpsoriasis in a subject, wherein the topical composition, comprisingabout 0.025% (w/w) of clobetasol propionate, is administered topicallyto the subject's affected skin area, wherein the said method providespost treatment mean clobetasol propionate plasma concentration issignificantly lower than that of TEMOVATE®. In some embodiments, thepost treatment mean clobetasol propionate plasma levels are less thanabout 150 pg/ml or the post treatment mean clobetasol propionate plasmalevels are less than about 130 pg/ml, or the post treatment meanclobetasol propionate plasma levels are less than about 100 pg/ml or thepost treatment mean clobetasol propionate plasma levels are less thanabout 75 pg/ml.

In some embodiments, the present invention provides a method of treatingpsoriasis in a subject, wherein the topical composition, comprising fromabout 0.025% (w/w) clobetasol propionate, is administered topically tothe subject's affected skin area, wherein the said method provides posttreatment mean clobetasol propionate plasma concentration issignificantly lower than that of TEMOVATE®. In some embodiments, thepost treatment mean clobetasol propionate plasma levels are less thanabout 150 pg/ml or the post treatment mean clobetasol propionate plasmalevels are less than about 130 pg/ml, or the post treatment meanclobetasol propionate plasma levels are less than about 100 pg/ml or thepost treatment mean clobetasol propionate plasma levels are less thanabout 75 pg/ml or the post treatment mean clobetasol propionate plasmalevels are less than about 50 pg/ml or the post treatment meanclobetasol propionate plasma levels are less than about 25 pg/ml or thepost treatment mean clobetasol propionate plasma levels are belowquantifiable level.

In another aspect of the present invention, psoriasis is mild tomoderate plaque psoriasis

In another aspect of the present invention, psoriasis is moderate tosevere plaque psoriasis.

In some embodiments, the present invention provides the post treatmentmean clobetasol propionate plasma levels are significantly less in thesubjects having no HPA axis suppression as compared to that of subjectswith HPA axis suppression.

In some embodiments, the method of treating psoriasis in a subject,involves the subject is having psoriatic lesions at least about 5% ofthe body surface area or the subject is having psoriatic lesions about5% to about 10% of the body surface area or the subject is havingpsoriatic lesions more than about 10% of the body surface area.

An aspect of the present invention relates to method of administering atopical composition comprising about 0.025% (w/w) clobetasol for thetreatment of psoriasis. The composition is administered twice daily fora period of about two weeks, or the composition is administered oncedaily for a period of about two weeks or the composition is administeredonce daily for a period of about four weeks or the composition isadministered twice daily for a period of about four weeks.

An aspect of the present invention relates to method of administering atopical composition comprising about 0.025% (w/w) clobetasol propionatefor the treatment of psoriasis. The composition is administered twicedaily for a period of about two weeks, or the composition isadministered once daily for a period of about two weeks or thecomposition is administered once daily for a period of about four weeksor the composition is administered twice daily for a period of aboutfour weeks.

In some embodiments, the composition of the present invention providessignificantly greater percent reduction in serum DHEAS concentration anda significantly greater mean post-treatment clobetasol propionate plasmaconcentration in subjects HPA axis suppression than subjects without HPAaxis suppression.

In another embodiment, a topical composition comprising about 0.025% w/wclobetasol, in which the percentage reduction in serum concentration ofdehydroepiandrosterone sulfate (DHEAS) in subjects with HPA axissuppression was significantly greater than in subjects without HPA axissuppression

In some embodiments, method of treating psoriasis, wherein the topicalcomposition of the present invention comprises about 0.025% (w/w)clobetasol and can be administered more than about 2 grams/day withsubstantially free of HPA axis suppression.

In some embodiments, method of treating psoriasis, wherein the topicalcomposition of the present invention comprises about 0.025% (w/w)clobetasol propionate and can be administered more than about 2grams/day with substantially free of HPA axis suppression.

In some embodiments, method of treating psoriasis, wherein the topicalcomposition of the present invention comprises about 0.025% (w/w)clobetasol and can be administered more than about 2 grams/day withlower percentage reduction of serum concentration of DHEAS.

In some embodiments, method of treating psoriasis, wherein the topicalcomposition of the present invention comprises about 0.025° % (w/w)clobetasol propionate and can be administered more than about 2grams/day with lower percentage reduction of serum concentration ofDHEAS.

In some embodiments, method of treating eczema, wherein the topicalcomposition of the present invention comprises about 0.025% (w/w)clobetasol and can be administered more than about 2 grams/day withlower percentage reduction of serum concentration of DHEAS.

In some embodiments, method of treating eczema, wherein the topicalcomposition of the present invention comprises about 0.025% (w/w)clobetasol propionate and can be administered more than about 2grams/day with lower percentage reduction of serum concentration ofDHEAS.

In some embodiments, the method comprises administering topicalcomposition, comprising about 0.025% (w/w) clobetasol, once or twicedaily with the dose of from about 1 gram to about 12 grams per day for aperiod of about one day to about two weeks. In another aspect, thecomposition is comprising about 0.025% (w/w) of clobetasol propionate.

In some embodiments, the method comprises administering a topicalcomposition, comprising about 0.025% (w/w) clobetasol, once or twicedaily with the dose of from about 0.1 mg to 3.15 mg per day ofclobetasol for a period of about two weeks. In another aspect,clobetasol is clobetasol propionate

In some embodiments, the method comprises administering topicalcomposition, comprising about 0.025% (w/w) clobetasol, once or twicedaily with the dose of from about 0.25 mg to 2.5 mg per day ofclobetasol for a period of about two weeks. In another aspect,clobetasol is clobetasol propionate

In some embodiments, the method comprises administering topicalcomposition, comprising about 0.025% (w/w) clobetasol, once or twicedaily with the dose of from about 0.25 mg to 2.5 mg per day ofclobetasol for a period of about two weeks. In another aspect,clobetasol is clobetasol propionate

In some embodiments, the topical composition of the present inventioncan be administered more than about 2 grams/day, but not exceeding about12 g/day for one week in the subject with eczema.

In some embodiments, the topical composition of the present inventioncan be administered more than about 60 g/week without causing clinicallysignificant HPA axis suppression in the subject.

In some embodiments, the present invention relates to a method oftreating psoriasis in a subject, the said method comprises administeringtopical composition, comprising about 0.025% (w/w) of clobetasol, onceor twice daily with a dose of from about 1 grams to about 7 grams perday of said topical composition for a period of about two weeks; whereinthe said method administers clobetasol from about 0.25 mg to about 2.5mg per day; and provides substantially free of HPA axis suppression andprovides a similar or improved therapeutic effect as compared to that ofthe topical composition comprising highest approved topical dose ofclobetasol i.e. TEMOVATE® and the said composition provides meanclobetasol plasma levels less than about 130 pg/mL. In another aspect,clobetasol is clobetasol propionate.

In some embodiments, the present invention relates to a method oftreating psoriasis in a subject, the said method comprises administeringtopical composition, comprising about 0.025% (w/w) of clobetasol, onceor twice daily with a dose of from about 1 grams to about 7 grams perday of said topical composition for a period of about two weeks; whereinthe said method administers clobetasol from about 0.25 mg to about 2.5mg per day; and provides lower percentage reduction of serumconcentration of DHEAS and provides a similar or improved therapeuticeffect as compared to that of the topical composition comprising highestapproved topical dose of clobetasol i.e. TEMOVATE® and the saidcomposition provides mean clobetasol plasma levels less than about 130pg/mL. In another aspect, clobetasol is clobetasol propionate.

In some embodiments, the present invention relates to a method oftreating psoriasis in a subject, the said method comprises administeringtopical composition, comprising about 0.025% (w/w) of clobetasol, onceor twice daily with the a dose of from about 1 grams to about 7 gramsper day of said topical composition for a period of two weeks; whereinthe said method administers clobetasol from about 0.25 mg to about 2.25mg per day; and the said method provides substantially free of adverseeffects and provides a similar or improved therapeutic effect of highestapproved topical dose of clobetasol i.e. TEMOVATE®. In some embodiments,the said method is treating psoriasis in a subjects having psoriaticlesions at least about 5% body surface area or treating psoriasis in asubjects having psoriatic lesions from about 5% to about 10% bodysurface area or treating psoriasis in a subjects having psoriaticlesions more than about 10% body surface area. In another aspect,clobetasol is clobetasol propionate.

In some embodiments, the topical composition of the present inventionprovides mean clobetasol plasma levels in the subjects, which is about 1fold less than the levels of topical composition comprising highestapproved topical dose of clobetasol i.e. 0.05% (w/w) or about 1.5 foldsless than the levels of topical composition comprising highest approvedtopical dose of clobetasol i.e. 0.05% (w/w) or about 2.5 folds less thanthe levels of topical composition comprising highest approved topicaldose of clobetasol i.e. 0.05% (w/w) or about 3.0 folds less than thelevels of topical composition comprising highest approved topical doseof clobetasol i.e. 0.05% (w/w) or about 3.5 folds less than the levelsof topical composition comprising highest approved topical dose ofclobetasol i.e. 0.05% (w/w) clobetasol with a similar or improvedtherapeutic efficacy.

In some embodiments, the therapeutic efficacy of the topical compositionof the present invention is equivalent or improved when compared to thatof the highest approved topical dose of clobetasol i.e. TEMOVATE®. Insome embodiments, at least 30% of the subject treated with the topicalcomposition of the present invention from severe or very severe,moderate to severe, or moderate to mild, minimal or almost clear orclear condition in the 15 days treatment.

In some embodiments, the topical composition of the present inventionforms a depot on the skin forming an occlusive film, thereby extendingthe duration of active agent action while allowing “breathing” of theskin.

In some embodiment, the compositions of the present invention may havepH values ranging from about 3.0 to about 7.0 or from about 3.5 to about6.0.

The compositions of the present invention can be dispensed in anydispensing device such as laminated tubes or lacquered aluminum tubes.Laminated tubes contains propylene glycol-free topical compositions,wherein the device is a lamitube comprised of 5 layers White PE,Ethylene acrylic acid (EAA), Aluminum foil. EAA, Virgin natural PE suchthat the composition is consistently discharge on application. Used. Inan embodiment, the compositions of the present invention are dispensedin lacquered aluminum tubes which are very useful and very effective instoring the cream.

The present invention is illustrated below by reference to the followingexamples. However, one skilled in the art will appreciate that thespecific methods and results discussed are merely illustrative of thepresent invention, and not to be construed as limiting the application.The following examples may include compilations of data that arerepresentative of data gathered at various times during the course ofdevelopment and experimentation related to the present invention.

EXAMPLES

The following general manufacturing processes were followed to prepareExamples 1-7:

Manufacturing Process I:

a) preparing an oil phase by melting and stirring stearyl alcohol, cetylalcohol; glyceryl stearate and PEG 100 stearate and lanolin followed bymethyl paraben and propyl paraben, and mineral oil,

b) preparing an aqueous phase by adding sorbitol solution into heatedpurified water,

c) preparing an emulsion by adding the oil phase of step (i) to theaqueous phase (ii) or vice versa under homogenization,

d) dissolving a premixed solution of clobetasol propionate in adiethylene glycol monoethyl ether and the followed by addition of BHTand homogenized to obtain a clobetasol propionate solution,

e) adding the clobetasol propionate solution obtained in step (iv) tothe emulsion prepared in step (iii) followed by homogenization to obtaina cream composition.

Manufacturing Process II:

a) preparing an oil phase by melting and stirring cetostearyl alcohol;whitewax; glyceryl stearate and PEG 100 stearate and isopropyl myristatefollowed by methyl paraben and propyl paraben, and cyclomethicone,

b) preparing an aqueous phase by heating the purified water,

c) preparing an emulsion by adding the oil phase of step (i) to theaqueous phase (ii) or vice versa under homogenization,

d) dissolving a premixed solution of clobetasol propionate in adiethylene glycol monoethyl ether and the followed by addition of BHTand homogenized to obtain a clobetasol propionate solution,

e) adding the clobetasol propionate solution obtained in step (iv) tothe emulsion prepared in step (iii) followed by homogenization to obtaina cream composition.

Example 1: Clobetasol Propionate (0.05% (w/w)) Cream

A composition of the present example was prepared by followingManufacturing Process-I using the following ingredient amounts.

Ingredient Percentage (w/w) Clobetasol propionate 0.05 Stearyl alcohol 2Cetyl alcohol 2 Glyceryl stearate & PEG 100 7.5 Lanolin 2 Mineral oil 5Sorbitol solution, 70% 2 Diethylene glycol monoethyl ether 3 Butylatedhydroxy toluene 0.05 Methyl paraben 0.2 Propyl paraben 0.4 Purifiedwater q.s to 100

Example 2: Clobetasol Propionate (0.025% (w/w)) Cream

A composition of the present example was prepared by followingManufacturing Process-I using the following ingredient amounts.

Ingredient Percentage (w/w) Clobetasol propionate 0.025 Stearyl alcohol2 Cetyl alcohol 2 Glyceryl stearate & PEG 100 stearate 7.5 Lanolin 2Mineral oil 5 Sorbitol solution, 70% 2 Diethylene glycol monoethyl ether10 Butylated hydroxy toluene 0.05 Methyl paraben 0.2 Propyl paraben 0.4Purified water q.s to 100

Example 3: Clobetasol Propionate (0.025% (w/w)) Cream

A composition of the present example was prepared by followingManufacturing Process-I using the following ingredient amounts.

Ingredient Percentage (w/w) Clobetasol propionate 0.025 Stearyl alcohol2 Cetyl alcohol 2 Glyceryl stearate & PEG 100 stearate 7.5 Lanolin 2Mineral oil 5 Sorbitol solution, 70% 2 Diethylene glycol monoethyl ether3 Butylated hydroxy toluene 0.05 Methyl paraben 0.2 Propyl paraben 0.4Purified water q.s to 100

Example 4: Clobetasol Propionate (0.025% (w/w)) Cream

A composition of the present example was prepared by followingManufacturing Process-I using the following ingredient amounts.

Ingredient Percentage (w/w) Clobetasol propionate 0.025 Stearyl alcohol1.5 Cetyl alcohol 2.5 Glyceryl stearate & PEG 100 stearate 7.5 Lanolin 3Mineral oil 4 Sorbitol solution, 70% 2 Diethylene glycol monoethyl ether5 Butylated hydroxy toluene 0.05 Methyl paraben 0.2 Propyl paraben 0.4Purified water q.s to 100

Example 5: Clobetasol Propionate (0.025% (w/w)) Cream

A composition of the present example was prepared by followingManufacturing Process-II using the following ingredient amounts.

Ingredient Percentage (w/w) Clobetasol propionate 0.025 Cetostearylalcohol 3 Glyceryl stearate & PEG 100 stearate 6 White wax 1 Diethyleneglycol monoethyl ether 3 Butylated hydroxy toluene 0.05 Isopropylmyristate 10 Cyclomethicone 5 Methyl paraben 0.2 Propyl paraben 0.4Purified water q.s to 100

Example 6: Clobetasol Propionate (0.025% (w/w)) Cream

A composition of the present example was prepared by followingManufacturing Process-II using the following ingredient amounts.

Ingredient Percentage (w/w) Clobetasol propionate 0.025 Cetostearylalcohol 3 Glyceryl stearate & PEG 100 stearate 6 White wax 1 Diethyleneglycol monoethyl ether 10 Butylated hydroxy toluene 0.05 Isopropylmyristate 10 Cyclomethicone 5 Methyl paraben 0.2 Propyl paraben 0.4Purified water q.s to 100

Example 7: Clobetasol Propionate (0.05% (w/w)) Cream

A composition of the present example was prepared by followingManufacturing Process-II using the following ingredient amounts.

Ingredient Percentage (w/w) Clobetasol propionate 0.05 Cetostearylalcohol 3 Glyceryl stearate & PEG 100 stearate 6 White wax 1 Diethyleneglycol monoethyl ether 10 Butylated hydroxy toluene 0.05 Isopropylmyristate 10 Cyclomethicone 5 Methyl paraben 0.2 Propyl paraben 0.4Purified water q.s to 100

Example 8

Physical and Chemical stability evaluation of the topical compositionsof the present invention: All the compositions were evaluated for thephysical changes such as color during the studies and all thecompositions were remained in the off white to white cream throughoutthe study and did not show any significant changes.

The prepared formulation of example 1, example 2, example 3, and example6 were filled into closed container and exposed to the various stabilitytesting conditions such as 25° C. and 60% relative humidity (RH), 30° C.and 65% RH, and 40° C. and 75% RH for twelve months, and analyses atvarious storage points are shown in Tables.

TABLE 1 Highest single Related unknown % Total Specification Assaycompound A impurity impurities Example 1 Initial 98.2 ND ND 0.0 1 M100.7 ND ND 0.0 30° C./65% RH 1 M 100.7 ND ND 0.0 40° C./75% RH 2 M100.4 ND ND 0.0 25° C./60% RH 2 M 99.4 ND ND 0.0 40° C./75% RH 3 M 99.6ND ND 0.0 25° C./60% RH 3 M 98.6 ND ND 0.0 30° C./65% RH 3 M 99.0 ND ND0.0 40° C./75% RH Example 2 Initial 102.0 ND ND 0.0 1 M 100.3 ND ND 0.030° C./65% RH 1 M 100.1 ND ND 0.0 40° C./75% RH 2 M 98.9 ND ND 0.0 30°C./65% RH 2 M 98.7 ND ND 0.0 40° C./75% RH 3 M 97.1 ND ND 0.0 25° C./60%RH 3 M 97.1 ND ND 0.0 30° C./65% RH 3 M 96.3 ND ND 0.0 40° C./75% RHExample 3 Initial 101.8 ND 0.14 0.19 1 M 103.3 ND 0.10 0.27 25° C./60%RH 1 M 100.8 ND 0.09 0.19 30° C./65% RH 1 M 100.4 ND 0.11 0.30 40°C./75% RH 2 M 99.2 ND 0.182 0.309 30° C./65% RH 2 M 99.0 ND 0.193 0.40440° C./75% RH 3 M 104.9 ND 0.17 0.40 25° C./60% RH 3 M 102.4 ND 0.170.46 30° C./65% RH Example 6 Initial 102.9 ND ND 0.0 1 M 101.9 ND ND 0.030° C./65% RH 1 M 101.3 ND ND 0.0 40° C./75% RH 2 M 102.3 ND ND 0.0 30°C./65% RH 2 M 101.1 ND ND 0.0 40° C./75% RH 3 M 98.3 ND ND 0.0 30°C./65% RH 3 M 99.5 ND ND 0.0 40° C./75% RH 6 M 99.9 — ND ND 25° C./60%RH 6 M 99.1 — ND ND 30° C./65% RH 6 M 98.4 — ND ND 40° C./75% RH 12 M2-8° C. 100.5 — 0.10 0.17 12 M 101.1 — 0.10 0.22 25° C./60% RH 12 M100.9 — 0.21 0.21 30° C./65% RH

Example 9: In Vitro Dissolution Study

Comparative in vitro dissolution profile testing, showing drug releasefrom Example 3 and Example 7 Vs. TEMOVATE E® cream, was conducted. Thecumulative percentage of drug released is shown in FIGS. 1 and 2 incomparison with TEMOVATE E® cream. The test was conducted as describedbelow:

A Franz diffusion cell was fitted with a 0.451 μm nylon membrane clampedbetween the donor and receptor compartments. The receptor media was amixture of water and acetone (35:65 by volume) with a replacement volumeof 11.0 mL, a sampling volume of 2.0 mL was drawn at 30 min, 1, 2, 4, 6,and 8 hours respectively, and the temperature was maintained at 32±0.5°C. About 200 mg of the formulation was applied uniformly over themembrane. The donor compartment was covered using PARAFILM® (hydrocarbonwax and polyolefin blend). Receptor fluid was analyzed for the drug,using high performance liquid chromatography (HPLC).

Example 10: In Vivo Efficacy Study

The UV erythema test is a suitable and accepted procedure forstandardized comparison of anti-inflammatory action of topicalmedications. In order to allow precise determination of the UV doses,individual sensitivity to UV were determined followed by performance ofa light scale to determine the minimal erythemal dose (MED).

UV exposure was performed using 1.5 MED, with less than 30 cm² skinsurface was irradiated. The pharmaceutical compositions given in theexamples and TEMOVATE E® cream were applied at the dose approximately 10mg/cm² over the UV exposed skin surface. The assessment of erythemasuppression will be determined by chromametric measurement.

The percent of inhibition of redness and AUC in comparison with TEMOVATEE® cream is shown in FIGS. 3 and 4, respectively.

While several particular forms of the application have been illustratedand described, it will be apparent that various modifications andcombinations of the application detailed in the text can be made withoutdeparting from the spirit and scope of the application.

Example 11: Effect on Endocrine Systems (Hypothalamic-Pituitary-AdrenalAxis Suppression Study)

Methods: This was 15 days, randomized, multicentre, multi-dose,comparator controlled, open label study, and the subjects were above 18years old with moderate to severe plaque psoriasis and they wererandomized to treatment with either Example 5 Cream or TEMOVATE® creamin a 1:1 ratio. These investigational products were applied twice dailyto all affected areas on the body excluding face, scalp, groin, axillaeand other intertriginous areas. The subjects had 20 to 50% BSA treatedto achieve maximal use exposure. The subjects were visited Screening,Baseline (Day 1), Day 8, Day 15 and Day 43 (if needed to confirmrecovery). Clinical determinations of disease severity was conductedusing the Investigator Global Assessment (IGA) for overall severity ateach visit. Subjects were tested for HPA axis function using the ACTHstimulation test (i.e., a cosyntropin i.v. or i.m. injection) at theScreening Visit (at least 14 days and no more than 28 days prior toBaseline) and at Day 15. In addition, blood samples for serumdehydroepiandrosterone sulfate (DHEAS) was taken at Screening, on Day 8and at the time of the ACTH stimulation test on Day 15 (pre-test sample)as a secondary measure of HPA axis suppression. At the time of thescreening ACTH stimulation test, a PK blood sample was taken to obtain abaseline value (PK screening sample). On Day 15, subjects were appliedthe last dose of study product at the clinic up to 60 minutes after apre-treatment PK blood sample was taken (0 hour-Day 15). PK bloodsamples was then collected at 1, 3 and 6 hours (+5 minutes) afterapplication of the study product.

Treatment regimen: Subjects were administered study product (Example 5),twice daily with approximately 12 hours between applications for 15 daysstarting on Day 1 during the study visit. Subjects had applied studyproduct to all affected areas except the face, scalp, groin, axillae andother intertriginous areas. The target dose was at least 5 to 7 g perday (1 teaspoon of cream, twice daily, applied at approximately 1 mg/cm2on 20% BSA-3000 cm2). All baseline affected areas and newly affectedareas have been treated until the end of the study even if cleared. Theinvestigator had marked the affected areas (in the source document),updated the marking at each visit, and reminded the subjects where studyproduct was to be applied at each visit using the marking. Study producthave been applied directly onto affected areas and rubbed in gently andcompletely. Study product have been applied after bathing, ifapplicable.

The changes in IGA score were evaluated on Day 1, Day 8, and Day 15. Thechange in IGA score from 4 to 0-1 was considered success in thetreatment as depicted below:

Score Grade Definition 0 None No plaque elevation above normal skinlevel may have residual non-erythematous discoloration no psoriaticscale no erythema 1 Minimal No more than: or very slight elevation abovenormal skin level Almost faint light pink coloration clear occasionalvery fine scale partially covering some of the lesions 2 Mild No morethan: slight but definite elevation of plaque above normal skin levellight red coloration fine scale with some lesions partially covered 3Moderate No more than: definite elevation with rounded or sloped edgesto plaque definite red coloration somewhat coarse scale with mostlesions partially covered 4 Severe/ At least one: Very marked elevationwith hard, sharp edges to Severe plaque dark red coloration coarse,thick scale with virtually all lesions mostly covered and a roughsurface

ACTH Stimulation Test

The subjects were tested for HPA axis function using the ACTHstimulation test (cosyntropin i.v. or i.m. injection) at a screeningvisit and at Day 15 visit. If HPA axis was suppressed at the Day 15visit, another test had been administered 28 days later (atapproximately Day 43) to confirm recovery. The ACTH stimulation testwere repeated approximately every 28 days until recovery is confirmed(or until the cause of suppression is diagnosed). The test should beconducted between the hours of 7:00 and 9:30 AM. The Screening Visittest must be normal to be eligible for the study (cortisol level >18ug/dL at 30 minutes post stimulation). The Day 15 test should beperformed within 1 hour of the time when the Screening Visit test wasperformed.

Serum DHEAS. Blood samples for serum DHEAS was taken at the time of thescreening ACTH stimulation test, on Day 8 and at the time of the ACTHstimulation test on Day 15 (pre-test sample) as a secondary measure ofHPA axis suppression.

It is observed that no significant HPA axis suppression was noted withExample 5 composition. The results of the HPA suppression study showed amuch lower potential for this adverse effect compared to TEMOVATE®(clobetasol propionate) Cream, 0.05% (w/w). With regard to therapeuticefficacy, Example 5 and TEMOVATE® were similar or almost identical inefficacy (IGA score), and with regard to HPA axis suppression, Example 5did not show clinically significant HPA axis suppression when comparedto that of TEMOVATE® cream.

Conclusion:

In summary, at the end of 15 days treatment with composition of Example5, about 50% of subjects were converted to “mild” and about 16.7% to“minimal or almost clear condition” from “moderate, severe/very severeconditions” as compared to 15 days treatment with TEMOVATE® creamwherein about 50% of subjects were converted to “mild” and 13.6% to“minimal or almost clear condition from moderate, severe/very severeconditions”.

Based on efficacy assessment as described in Table 2 (Example5—clobetasol 0.025% (w/w) cream and TEMOVATE® Cream—0.05% (w/w)), boththe compositions had shown similar or almost identical therapeuticefficacy.

With regard to the results of HPA axis suppression (Table 3 and Table4), composition of the present invention (Example 5) had shown about12.5% of the total subjects had HPA suppression i.e. 3 subjects out of24 had HPA axis suppression, whereas TEMOVATE® cream had shown about36.4% of the total subjects had HPA axis suppression i.e. 8 subjects outof 22 had HPA axis suppression. The mean plasma levels of clobetasol forTEMOVATE® was around 2.5 times more than that of Example 5, confirmingthe much lower systemic exposure by Example 5 composition and theaverage post-treatment plasma levels of clobetasol was significantlylower for the Example 5 composition (Table 7).

The subjects with HPA axis suppression had about more than 3 times meanplasma clobetasol levels of those without HPA axis suppression whichvalidated that the higher exposure leads to more HPA axis suppression(Table 8).

Table 3 shows the result of ACTH stimulation test and Table 5 and 6shows serum DHEAS levels during HPA axis suppression.

TABLE 2 Efficacy Analysis: Investigator's Global Assessment (IGA) -Example 5 Vs TEMOVATE ® Cream Day 1 Day 8 Day 15 Test drugs Conditionlevel No. (%) No. (%) No. (%) Example 5 None 0 (0) 0 (0)   0 (0)  (Number of Minimal or 0 (0) 1 (4.2) 4 (16.7) subjects = 24) Almost clearMild 0 (0) 6 (25)  12 (50)   Moderate   19 (79.2) 16 (66.7) 7 (29.2)Severe/Very   5 (20.8) 1 (4.2) 1 (4.2)  Severe TEMOVATE ® None 0 (0) 0(0)   1 (4.5)  (Number of Minimal or 0 (0) 1 (4.5) 3 (13.6) subjects =22) Almost clear Mild 0 (0)  6 (27.3) 11 (50)   Moderate   15 (68.2) 13(59.1) 7 (31.8) Severe/Very   7 (31.8) 2 (9.1) 0 (0)   Severe

TABLE 3 ACTH Stimulation Test Result (Serum Cortisol levels in ug/dL)Study Visit: TEMOVATE ® Time Point Statistics Example 5 Cream Screening:N 24 22 Pre- Mean ± 11.65 ± 5.392 12.43 ± 4.641 Stimulation SD Median11.45 13.15 Screening: N 24 22 Post- Mean ± 24.42 ± 2.912 26.12 ± 3.938Stimulation SD Median 24.3 25.3 Day 15: Pre- N 24 22 Stimulation Mean ±10.94 ± 6.247  9.11 ± 6.596 SD Median  8.95  7.9 Day 15: Post- N 24 22Stimulation Mean ± 23.07 ± 5.942 20.38 ± 6.490 SD Median 23.65 20

TABLE 4 Results of HPA axis suppression (ACTH stimulation test)TEMOVATE ® Example 5 Cream % HPA Suppression* 12.5 36.4 Total Number ofSubjects 24   22   Number of Subjects with HPA 3 out of 24 8 out of 22axis suppression subjects subjects Applied dose (percentage) 0.025%(w/w) 0.05% (w/w) HPA suppression is considered as cortisol level<=18.00 ug/dL at 30 minutes post stimulation

TABLE 5 Serum DHEAS Concentration (ug/dL) TEMOVATE ® Study VisitStatistics Example 5 Cream Screening N 24 22 Mean ± 176.9 ± 97.26 135.6± 91.51  SD Median  174.5  116.5 Day 8 N 24 22 Mean ± 169.6 ± 97.68122.9 ± 120.47 SD Median  187.5 90 Absolute change N 24 22 fromScreening to Mean ±  7.3 ± 33.20 12.7 ± 71.53 Day 8 SD Median  4   24.5Percent change N 23 22 from Screening to Mean ±  6.83 ± 28.261 19.70 ±39.739 Day 8 SD Median    2.53   24.77 Day 15 N 24 22 Mean ± 148.8 ±80.31 114.7 ± 100.76 SD Median  168.5 82 Absolute change N 24 22 fromScreening to Mean ±  28.1 ± 52.73 20.9 ± 60.25 Day 15 SD Median 22 26Percent change N 23 22 from Screening to Mean ±  11.04 ± 26.966 21.62 ±46.406 Day 15 SD Median   16.13   28.4

TABLE 6 Serum DHEAS Concentration (ug/dL) by Subject Status of HPA AxisSuppression With HPA Without HPA Axis Axis Study Visit StatisticsSuppression Suppression Day 8 N 11 35 Mean ± 111.5 ± 86.83  158.5 ±115.74  SD Median 83 130  Absolute change N 11 35 from Screening to Mean± 36.3 ± 25.12 1.6 ± 58.61 Day 8 SD Median 34  7 Percent change N 11 34from Screening to Mean ± 34.72 ± 29.699 6.13 ± 33.476 Day 8 SD Median  29.66    9.37 Day 15 N 11 35 Mean ± 74.1 ± 61.58 150.9 ± 91.97  SDMedian 54 140  Absolute change N 11 35 from Screening to Mean ± 73.7 ±41.62 9.2 ± 51.05 Day 15 SD Median 62 20 Percent change N 11 34 fromScreening to Mean ± 54.78 ± 20.228 3.73 ± 33.363 Day 15 SD Median  52.54   13.8

TABLE 7 Plasma Concentrations of Clobetasol Propionate (pg/mL) Visit:Time TEMOVATE ® Point Statistics Example 5 Cream Screening N 24 22 Mean± 0.000 ± 0.0000 2.040 ± 9.5663 SD Median  0  0 Day 15: Pre- N 24 22Treatment (0 Mean ± 50.651 ± 96.0016 130.735 ± 146.1732 hour) SD Median  27.97   81.1 Day 15: 1 N 23 22 Hour Mean ±  60.919 ± 142.7070 166.949± 183.3209 SD Median   31.42   115.735 Day 15: 3 N 24 21 Hours Mean ±50.445 ± 71.1675 156.968 ± 144.6841 SD Median   28.09   128.36 Day 15: 6N 24 21 Hours Mean ± 58.825 ± 99.1553 146.324 ± 131.2930 SD Median   30.325   125.86 Average of N 22 22 Post- Mean ±  56.339 ± 104.6688152.458 ± 140.8674 Treatment SD Median   29.45   131.54

TABLE 8 Plasma Concentrations of Clobetasol Propionate (pg/mL) bySubject Status of HPA Axis Suppression With HPA Without HPA Visit: TimeAxis Axis Point Statistics Suppression Suppression Screening N 11 35Mean ± 0.000 ± 0.0000 1.282 ± 7.5844  SD Median  0  0 Day 15: Pre- N 1135 Treatment (0 Mean ± 195.691 ± 150.7514 55.406 ± 100.3403 hour) SDMedian   136.49   26.23 Day 15: 1 Hour N 11 34 Mean ± 210.873 ± 196.290481.012 ± 151.2306 SD Median   155.88   31.73 Day 15: 3 Hours N 11 34Mean ± 200.668 ± 126.0445 67.637 ± 103.9073 SD Median   195.45    33.185Day 15: 6 Hours N 11 34 Mean ± 205.386 ± 147.4279 65.451 ± 91.5422  SDMedian   178.05   36.26 Average of Post- N 10 34 Treatment Mean ±217.123 ± 153.7979 71.244 ± 106.0424 SD Median  185.565   31.74

While several particular forms of the application have been illustratedand described, it will be apparent that various modifications andcombinations of the application detailed in the text can be made withoutdeparting from the spirit and scope of the application.

All publications, patents, and patent applications mentioned in thisspecification are herein incorporated by reference to the same extent asif each individual publication, patent, or patent application wasspecifically and individually indicated to be incorporated by reference.

1.-12. (canceled)
 13. A method of treating moderate to severe plaquepsoriasis in a subject comprising: administering to the subject twicedaily, for a period of up to about two weeks, a topical compositioncomprising about 0.025% (w/w) of clobetasol, an oil phase; an aqueousphase; and at least one pharmaceutically acceptable excipient; whereinthe oil phase comprises at least one penetration enhancing agent in anamount from about 0.01% to about 15.0% of the total weight of thecomposition and a non-polymeric thickening agent; wherein the at leastone penetration enhancing agent is diethylene glycol monoethyl ether;wherein the at least one pharmaceutically acceptable excipient isisopropyl myristate; and wherein treating moderate to severe plaquepsoriasis in the subject results in an investigator global assessmentscore of 0 to
 1. 14. The method of claim 13, wherein the investigatorglobal assessment score is measured at day
 15. 15. The method of claim13, wherein treating moderate to severe plaque psoriasis in the subjectresults in at least 70% of subjects not having hypothalamic pituitaryadrenal (HPA) axis suppression.
 16. The method of claim 13, whereintreating moderate to severe plaque psoriasis in the subject results inat least 80% of subjects not having hypothalamic pituitary adrenal (HPA)axis suppression.
 17. The method of claim 13, wherein treating moderateto severe plaque psoriasis in the subject results in at least 90% ofsubjects not having hypothalamic pituitary adrenal (HPA) axissuppression.
 18. The method of claim 13, wherein treating moderate tosevere plaque psoriasis in the subject results in the subject beingsubstantially free of adverse effects.
 19. The method of claim 18,wherein the adverse effect is skin irritation.
 20. The method of claim13, wherein the topical composition provides a mean clobetasol plasmalevel less than about 150 pg/mL.
 21. The method of claim 13, wherein thetopical composition provides a mean clobetasol plasma level less thanabout 130 pg/mL.
 22. The method of claim 13, wherein the subject hasmoderate to severe plaque psoriatic lesions involving at least about 5%body surface area.
 23. The method of claim 13, wherein the subject hasmoderate to severe plaque psoriatic lesions involving at least about 10%body surface area.
 24. The method of claim 13, wherein the clobetasol isclobetasol propionate.
 25. The method of claim 13, wherein thenon-polymeric thickening agent is cetosteryl alcohol.
 26. The method ofclaim 13, wherein the at least one pharmaceutically acceptable excipientis selected from the group consisting of a carrier, emulsifier,co-emulsifier, solvent, co-solvents, emollient, antioxidant,preservative, gelling or thickening agent, polymer, surfactant, soothingagent, pH modifier, solubilizer, humectants, moisturizer, oily base, andany combination thereof.
 27. The method of claim 26, wherein the atleast one pharmaceutically acceptable excipient is an emulsifier and theemulsifier is a mixture of glyceryl stearate and PEG 100 stearate. 28.The method of claim 27, wherein the mixture of glyceryl stearate and PEG100 Stearate is about 6% of the total weight of the composition.
 29. Themethod of claim 13, wherein the isopropyl myristate is about 10% of thetotal weight of the composition.
 30. The method of claim 26, wherein theat least one pharmaceutically acceptable excipient is an emollient andthe emollient is cyclomethicone.
 31. The method of claim 30, wherein thecyclomethicone is about 5% of the total weight of the composition. 32.The method of claim 26, wherein the at least one pharmaceuticallyacceptable excipient is an antioxidant and the antioxidant is butylatedhydroxytoluene.
 33. The method of claim 32, wherein the butylatedhydroxytoluene is about 0.05% of the total weight of the composition.34. The method of claim 26, wherein the at least one pharmaceuticallyacceptable excipient is a preservative and the antioxidant is selectedfrom methylparaben, propylparaben and a combination thereof.
 35. Themethod of claim 34, wherein the preservative is methylparaben and themethylparaben is about 0.2% of the total weight of the composition. 36.The method of claim 34, wherein the preservative is propylparaben andthe propylparaben is about 0.4% of the total weight of the composition.37. The method of claim 26, wherein the at least one pharmaceuticallyacceptable excipient is a gelling or thickening agent and the gelling orthickening agent is white wax.
 38. The method of claim 37, wherein thewhite wax is about 1% of the total weight of the composition.
 39. Themethod of claim 13, wherein the aqueous phase is water.
 40. The methodof claim 39, the water is at least 60% of the total weight of thecomposition.
 41. The method of claim 13, wherein the topical compositionis substantially free of propylene glycol.
 42. The method of claim 13,wherein the topical composition is substantially free of polymers. 43.The method of claim 13, wherein the oil phase comprises at least onepenetration enhancing agent in an amount from about 0.01% to about 10.0%of the total weight of the composition, wherein the at least onepenetration enhancing agent is diethylene glycol monoethyl ether. 44.The method of claim 13, wherein the oil phase comprises at least onepenetration enhancing agent in an amount up to about 5.0% of the totalweight of the composition, wherein the at least one penetrationenhancing agent is diethylene glycol monoethyl ether.
 45. The method ofclaim 13, wherein the oil phase comprises at least one penetrationenhancing agent in an amount of about 3.0% of the total weight of thecomposition, wherein the at least one penetration enhancing agent isdiethylene glycol monoethyl ether.
 46. The method of claim 13, whereinthe topical composition comprises about 0.025% clobetasol; an oil phaseof about 3% diethylene glycol monoethyl ether as the penetrationenhancing agent and about 1% white wax as the non-polymeric thickeningagent; about 10% isopropyl myristate; water as the aqueous phase; andwherein the at least one pharmaceutically acceptable excipient is about6% of a mixture of glyceryl stearate and PEG 100 stearate, about 0.05%butylated hydroxytoluene, about 5% cyclomethicone, about 0.2%methylparaben; and about 0.4% propylparaben.